Original Article
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
N Engl J Med 2009; 361:947-957September 3, 2009
- Abstract
Background
Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non–small-cell lung cancer.
Methods
In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients). The primary end point was progression-free survival.
Results
The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin–paclitaxel. The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin–paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). In the subgroup of 261 patients who were positive for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin–paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P<0.001), whereas in the subgroup of 176 patients who were negative for the mutation, progression-free survival was significantly longer among those who received carboplatin–paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P<0.001). The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin–paclitaxel group.
Conclusions
Gefitinib is superior to carboplatin–paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, NCT00322452.)
Media in This Article
Figure 1
Screening, Group Assignment, and Inclusion in Analyses.Figure 2
Kaplan–Meier Curves for Progression-free Survival.Article Activity
- Article
Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase have clinical efficacy, as compared with the best supportive care1 or standard chemotherapy,2 when given as second-line or third-line therapy for advanced non–small-cell lung cancer. Treatment with EGFR tyrosine kinase inhibitors is most effective in women, patients who have never smoked, patients with pulmonary adenocarcinomas, and patients of Asian origin. In these populations, such treatment is associated with favorable rates of objective responses, progression-free survival, and overall survival.1,3,4 These populations also have a relatively high incidence of somatic mutations in the region of the EGFR gene that encodes the tyrosine kinase domain.5,6 Studies have shown that in patients with pulmonary adenocarcinoma who had a base-pair deletion at exon 19 (del746_A750) or a point mutation at exon 21 (L858R), the tumors were highly responsive to EGFR tyrosine kinase inhibitors,7-9 and subsequent studies of first-line therapy with these agents showed objective response rates of 54.8 to 81.6% and progression-free survival of 9.7 to 13.3 months among patients with these mutations.10-12
On the basis of these and other studies,1,4,13-16 we hypothesized that in a selected population, first-line therapy with an oral EGFR tyrosine kinase inhibitor would be at least as effective as chemotherapy with carboplatin–paclitaxel. In this study, we compared the efficacy, safety, and adverse-event profile of gefitinib with those of carboplatin–paclitaxel when these drugs were used as first-line treatment in nonsmokers or former light smokers in East Asia who had adenocarcinoma of the lung. We also examined the role of an EGFR mutation as a predicator of the efficacy of gefitinib or carboplatin–paclitaxel.
Methods
Study Design and Patients
The First Line Iressa versus Carboplatin/Paclitaxel in Asia (Iressa Pan-Asia Study [IPASS]) study was a phase 3, multicenter, randomized, open-label, parallel-group study comparing gefitinib (Iressa, AstraZeneca) with carboplatin (Paraplatin, Bristol-Myers Squibb) plus paclitaxel (Taxol, Bristol-Myers Squibb) as first-line treatment in clinically selected patients in East Asia who had advanced non–small-cell lung cancer. The primary end point was progression-free survival. Secondary end points included overall survival (an early analysis, since follow-up is ongoing), the objective response rate, quality of life, reduction in symptoms, safety, and the adverse-event profile. Evaluations of efficacy according to the baseline biomarker status of EGFR were planned exploratory objectives.
Patients were eligible for inclusion in the study if they were 18 years of age or older, had histologically or cytologically confirmed stage IIIB or IV non–small-cell lung cancer with histologic features of adenocarcinoma (including bronchoalveolar carcinoma), were nonsmokers (defined as patients who had smoked <100 cigarettes in their lifetime) or former light smokers (those who had stopped smoking at least 15 years previously and had a total of ≤10 pack-years of smoking), and had had no previous chemotherapy or biologic or immunologic therapy. Other eligibility criteria are described in the Supplementary Appendix, available with the full text of this article at NEJM.org.
The principal investigators and the members of the steering committee (see the Appendix at the end of this article) designed the study in collaboration with the sponsor (AstraZeneca) and supervised the conduct of the trial. The sponsor collected and analyzed the data. The lead academic author had unrestricted access to the data and vouches for the validity and completeness of the results of the trial (see the Supplementary Appendix for further details). All patients provided written informed consent; separate consent was provided for the assessment of EGFR biomarkers. An independent ethics committee at each participating institution approved the study protocol. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, applicable regulatory requirements, and AstraZeneca's policy on bioethics. One planned interim analysis was performed by an independent statistician and reviewed by an independent data and safety monitoring committee (see the Supplementary Appendix).
Study Treatment
Patients were randomly assigned, in a 1:1 ratio, to receive gefitinib (250 mg per day, administered orally) or paclitaxel (200 mg per square meter of body-surface area, administered intravenously over a 3-hour period on the first day of the cycle) followed immediately by carboplatin (at a dose calculated to produce an area under the concentration–time curve of 5.0 or 6.0 mg per milliliter per minute, administered intravenously over a period of 15 to 60 minutes) in cycles of once every 3 weeks for up to 6 cycles. Randomization was performed with the use of dynamic balancing17 with respect to performance status, as assessed by the World Health Organization (WHO) performance scale measuring activity (0 or 1, or 2 on a scale of 0 to 4, with lower numbers indicating a higher degree of activity); smoking status (nonsmoker or former light smoker); sex; and center. Treatment continued until progression of the disease, development of unacceptable toxic effects, a request by the patient or physician to discontinue treatment, serious noncompliance with the protocol, or completion of six chemotherapy cycles. Among patients assigned to gefitinib therapy, those whose tumor progressed were offered the opportunity to switch to treatment with carboplatin–paclitaxel; however, if the patient declined or was not a good candidate for that treatment, he or she could receive another approved therapy of the physician's choice. Among patients who were receiving carboplatin–paclitaxel, further therapy after progression of the disease was at the physician's discretion.
Assessments
Progression-free survival was assessed from the date of randomization to the earliest sign of disease progression, as determined by means of the Response Evaluation Criteria in Solid Tumors (RECIST),18 or death from any cause. Overall survival was assessed from the date of randomization until death from any cause. Tumor response was assessed every 6 weeks until disease progression. Quality of life was assessed with the use of the Functional Assessment of Cancer Therapy–Lung (FACT–L) questionnaire (in which scores range from 0 to 136, with higher scores indicating better quality of life) and the Trial Outcome Index (TOI, which is the sum of the physical well-being, functional well-being, and lung-cancer subscale [LCS] scores of FACT-L; scores range from 0 to 84, with higher scores indicating better quality of life), and symptoms were assessed with the use of the LCS score (scores range from 0 to 28, with higher scores indicating fewer symptoms). The FACT-L questionnaire19 was administered at randomization and at week 1, once every 3 weeks until day 127, once every 6 weeks from day 128 until disease progression, and when the study drug was discontinued. Clinically relevant improvement was predefined as an improvement of six points or more in FACT-L and TOI scores or an improvement of two points or more in LCS scores, with the higher scores maintained for at least 21 days.20 Safety and tolerability were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Tumor samples from patients who consented to have biomarkers assessed were analyzed at two central laboratories to determine biomarker status, with EGFR mutation status the first priority. Patients were considered to be positive for the EGFR mutation if 1 of 29 EGFR mutations was detected with the use of the amplification refractory mutation system (ARMS) and the DxS EGFR29 mutation-detection kit.21,22
Statistical Analysis
The primary end point (progression-free survival) was analyzed with the use of a Cox proportional-hazards model in the intention-to-treat population (all randomly assigned patients) to assess the noninferiority of gefitinib as compared with carboplatin–paclitaxel, with the WHO performance status (0 or 1, or 2), smoking status (nonsmoker or former light smoker), and sex as covariates. For noninferiority to be demonstrated, the 95% confidence interval for the hazard ratio had to lie entirely below the predefined noninferiority limit of 1.2. We estimated that with a total of 944 progression events, the study would have 80% power to demonstrate noninferiority if the treatments were truly equal, with a two-sided 5% probability of an erroneous demonstration of noninferiority. If the 95% confidence interval for the hazard ratio was also below 1, the P value would be less than 0.05 and superiority could be concluded from the same analysis without statistical penalty (closed test procedure).23 Supportive secondary analyses are described in the Supplementary Appendix. Planned subgroup analyses were performed to compare progression-free survival between treatments in groups defined according to WHO performance status (0 or 1, or 2), smoking status (nonsmoker or former light smoker), sex, age at randomization (<65 years or ≥65 years), disease stage at screening (stage IIIB or IV), and presence or absence of biomarkers. Tests to determine interactions of treatment with covariates were used to identify predictive factors by assessing whether there was a significant difference in the treatment effect for progression-free survival (hazard ratio for progression or death) between subgroups.
Overall survival was analyzed with the use of methods that were similar to those used for the analysis of progression-free survival. The results of an early analysis are presented; follow-up with respect to overall survival is ongoing. The objective response rate (in the intention-to-treat population) and quality of life and rates of symptom reduction (among all patients with a baseline and at least one post-baseline quality-of-life assessment that could be evaluated) were assessed with the use of a logistic-regression model with the same covariates as those considered for progression-free survival to calculate odds ratios and 95% confidence intervals. Planned subgroup analyses of the objective response rate were performed with the use of methods that were similar to those used for the analysis of progression-free survival.
Adverse events were summarized for all patients who received at least one dose of the assigned study treatment. The incidence rates of 10 specified safety events (5 that were possibly associated with each study treatment) were compared with the use of Fisher's exact test; adjustment for multiple comparisons was performed with the use of the method of Westfall and Young.24
Results
Patients and Treatment
From March 2006 through October 2007, a total of 1217 patients from 87 centers in Hong Kong, elsewhere in China, Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan, and Thailand were randomly assigned to a study group (Figure 1Figure 1
Screening, Group Assignment, and Inclusion in Analyses.). The two groups were well balanced with respect to demographic and baseline characteristics (Table 1Table 1
Demographic and Baseline Characteristics in the Intention-to-Treat Population.). The mean duration of treatment was 6.4 months (median, 5.6; range, 0.1 to 22.8) for gefitinib and 3.4 months (median, 4.1; range, 0.7 to 5.8) for carboplatin–paclitaxel. The median number of treatment cycles in the carboplatin–paclitaxel group was six. At the cutoff date for collection of data (April 14, 2008), a total of 24.5% of the patients in the gefitinib group were continuing to receive the study treatment; all patients in the carboplatin–paclitaxel group had discontinued the drugs. After discontinuation of the assigned treatment at any time during the study, 38.9% of the patients in the gefitinib group received carboplatin–paclitaxel, and 39.5% of the patients in the carboplatin–paclitaxel group received an EGFR tyrosine kinase inhibitor; 10.5% of the patients in the gefitinib group and 14.0% of those in the carboplatin–paclitaxel group received other anticancer treatments.Efficacy
The median follow-up period for the analysis of progression-free survival was 5.6 months. The median progression-free survival was 5.7 months in the gefitinib group and 5.8 months in the carboplatin–paclitaxel group, approximately coinciding with crossing of the Kaplan–Meier curves. The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin–paclitaxel; a total of 950 patients had progression of disease. The study met its primary objective of demonstrating noninferiority and showed the superiority of gefitinib as compared with carboplatin–paclitaxel for progression-free survival (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). The probability that a patient would be free of disease progression was greater with carboplatin–paclitaxel in the first 6 months and greater with gefitinib in the following 16 months (Figure 2AFigure 2
Kaplan–Meier Curves for Progression-free Survival.). Progression-free survival was longer in the gefitinib group than in the carboplatin–paclitaxel group in all clinical subgroups; the only clinical factor that affected progression-free survival was age (<65 years: hazard ratio, 0.81; 95% CI, 0.70 to 0.95; P=0.007; ≥65 years: hazard ratio, 0.58; 95% CI, 0.45 to 0.76; P<0.001; P=0.03 for the interaction of treatment with age) (Fig. 1 in the Supplementary Appendix).A total of 1038 patients (85.3%) gave their consent for biomarker analyses, and 683 patients (56.1%) provided samples. EGFR mutation data for 437 patients (35.9%) could be evaluated. Patients with a tissue sample that could be evaluated had demographic characteristics that were similar to those of the overall population (Table 1 in the Supplementary Appendix). Of the 437 samples, 261 (59.7%) were positive for a mutation. Of these 261 samples, 140 (53.6%) had exon 19 deletions, 111 (42.5%) had a mutation at exon 21 (L858R), 11 (4.2%) had a mutation at exon 20 (T790M), and 10 (3.8%) had other mutations; 11 patients had multiple mutations. The proportions of mutations were well balanced between the two groups (Table 2 in the Supplementary Appendix).
There was a significant interaction between treatment and EGFR mutation with respect to progression-free survival (P<0.001). Progression-free survival was significantly longer among patients receiving gefitinib than among those receiving carboplatin–paclitaxel in the mutation-positive subgroup (hazard ratio for progression, 0.48; 95% CI, 0.36 to 0.64; P<0.001) (Figure 2B) and significantly shorter among patients receiving gefitinib than among those receiving carboplatin–paclitaxel in the mutation-negative subgroup (hazard ratio, 2.85; 95% CI, 2.05 to 3.98; P<0.001) (Figure 2C). Results in the subgroup with unknown EGFR-mutation status (hazard ratio with gefitinib, 0.68; 95% CI, 0.58 to 0.81; P<0.001) (Figure 2D) were similar to those for the overall population.
The objective response rate in the overall population was significantly higher with gefitinib than with carboplatin–paclitaxel (43.0% vs. 32.2%; odds ratio, 1.59; 95% CI, 1.25 to 2.01; P<0.001) (Table 3 in the Supplementary Appendix) and numerically or statistically greater with gefitinib in all clinical subgroups. The objective response rate was 71.2% with gefitinib versus 47.3% with carboplatin–paclitaxel in the mutation-positive subgroup (P<0.001) and 1.1% (one patient) versus 23.5%, respectively, in the mutation-negative subgroup (P=0.001) (Table 3 in the Supplementary Appendix).
Overall survival in this early analysis (450 patients [37.0%] died, with follow-up ongoing) was similar between the two groups in the overall population (hazard ratio for death in the gefitinib group, 0.91; 95% CI, 0.76 to 1.10) (Fig. 2A in the Supplementary Appendix). Median survival was 18.6 months among patients receiving gefitinib and 17.3 months among patients receiving carboplatin–paclitaxel. After observing the results with respect to progression-free survival, we performed an analysis of overall survival according to mutation status, although this analysis included only 81 deaths in the mutation-positive subgroup and 94 in the mutation-negative subgroup. The hazard ratios with gefitinib were 0.78 (95% CI, 0.50 to 1.20) in the mutation-positive subgroup and 1.38 (95% CI, 0.92 to 2.09) in the mutation-negative subgroup (Fig. 2B and 2C in the Supplementary Appendix).
Significantly more patients in the gefitinib group than in the carboplatin–paclitaxel group had a clinically relevant improvement in quality of life, as assessed by scores on the FACT-L questionnaire (odds ratio, 1.34; 95% CI, 1.06 to 1.69; P=0.01) and by scores on the TOI (odds ratio, 1.78; 95% CI, 1.40 to 2.26; P<0.001) (Figure 3Figure 3
Rates of Improvement in Scores for Quality for Life and Symptoms.). Rates of reduction in symptoms, as assessed on the basis of the LCS scores, were similar between patients who received gefitinib and those who received carboplatin–paclitaxel (odds ratio with gefitinib, 1.13; 95% CI, 0.90 to 1.42; P=0.30) (Figure 3). Results according to mutation status are provided in Fig. 3 in the Supplementary Appendix.Safety and Adverse-Event Profile
Table 2Table 2
Adverse Events. lists the most common adverse events. Gefitinib, as compared with carboplatin–paclitaxel, was associated with a lower rate of grade 3 or 4 adverse events, as defined according to the Common Terminology Criteria for Adverse Events (28.7% vs. 61.0%), a lower rate of adverse events leading to discontinuation of the drug (6.9% vs. 13.6%), and a lower rate of dose modification due to toxic effects (16.1% vs. 35.2% for carboplatin and 37.5% for paclitaxel). Adverse events leading to death occurred in 3.8% of the patients treated with gefitinib and in 2.7% of the patients treated with paclitaxel–carboplatin; serious adverse events, including death, occurred in 16.3% and 15.6% of patients in the two groups, respectively; and serious adverse events leading to hospitalization occurred in 13.8% and 13.1% of patients in the two groups, respectively. The incidences of rash or acne, diarrhea, and elevated liver aminotransferase levels were significantly higher with gefitinib than with carboplatin–paclitaxel, whereas the incidences of neurotoxic effects, nausea and vomiting, and hematologic toxic effects were significantly higher with carboplatin–paclitaxel (Table 4 in the Supplementary Appendix). Interstitial-lung-disease events (i.e., the acute respiratory distress syndrome, interstitial lung disease, pneumonitis, or radiation pneumonitis) occurred in 16 patients treated with gefitinib (2.6%), 3 of whom died, and in 8 patients treated with carboplatin-paclitaxel (1.4%), 1 of whom died.Discussion
Platinum-based combination chemotherapy, such as carboplatin–paclitaxel, is the standard first-line therapy for advanced non–small-cell lung cancer.25,26 The results of this trial showed that gefitinib by itself is superior to carboplatin–paclitaxel in a selected population of East Asian patients.
As initial treatment of non–small-cell lung cancer in East Asian nonsmokers or former light smokers with pulmonary adenocarcinoma, gefitinib, as compared with carboplatin–paclitaxel, prolonged progression-free survival, increased the objective response rate, reduced toxic effects, and improved quality of life. The overall benefit was driven primarily by the subgroup of patients with EGFR mutations; in this subgroup, patients treated with gefitinib, as compared with those treated with carboplatin–paclitaxel, had a remarkably high objective response rate (71.2%) and prolonged progression-free survival (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P<0.001). In the subgroup of patients without EGFR mutations, the objective response rate with gefitinib was 1.1%, and progression-free survival favored chemotherapy (hazard ratio with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P<0.001). These contrasting outcomes probably explain the change over time in treatment effect for progression-free survival in the overall population. The initial superiority of carboplatin–paclitaxel was attributed to the benefit that the EGFR-mutation–negative subgroup received from chemotherapy but not from gefitinib, whereas prolonged progression-free survival in the EGFR-mutation–positive subgroup explained the subsequent improvement favoring gefitinib. Crossing of the Kaplan–Meier curves did not occur in the mutation-positive subgroup or the mutation-negative subgroup.
Lynch et al. found specific EGFR mutations that correlated with tumor response to gefitinib.7 In the Iressa Survival Evaluation in Lung Cancer trial (ISEL; ClinicalTrials.gov number, NCT00242801), the objective response rate for gefitinib-treated patients was 37.5% among the 16 patients with a tumor bearing an EGFR mutation as compared with 2.6% among the 116 patients without a mutation.27 Our trial confirms the predictive value of EGFR mutations for the responsiveness of pulmonary adenocarcinoma to gefitinib as compared with carboplatin–paclitaxel. The difference in the rates of objective response between gefitinib-treated patients with an EGFR mutation and those without an EGFR mutation (71.2% vs. 1.1%) was remarkable. The rate of an objective response to first-line gefitinib in our study is similar to rates reported in other studies in which patients were selected according to EGFR-mutation status, including patients in Western countries.10,12,28 Sequist et al. screened patients (who were selected on the basis of clinical characteristics) for an EGFR mutation and reported an objective response rate of 54.8% among 31 gefitinib-treated patients who were positive for an EGFR mutation, only 2 of whom were Asian.12 However, in our study, objective response rates among patients without an EGFR mutation were lower than expected, given the results of previous studies.16,29 One possible explanation is our use of ARMS, a more sensitive technique for detecting EGFR mutations.21,22 When Zhu et al. used ARMS to reanalyze 148 samples that had previously been classified as negative for an EGFR mutation, they found 11 new samples with exon 19 mutations.30 Another possible explanation is that studies that showed higher response rates among mutation-negative patients were not always conducted in previously untreated patients. Mutation-negative status that is determined in a diagnostic sample obtained at the time of the initial presentation may change during subsequent tumor progression or during the course of chemotherapy.31
Our findings suggest that, whenever possible, EGFR-mutation status should be determined before the initial treatment of pulmonary adenocarcinoma. Ethnic origin, smoking status, and histologic findings help to identify patients who have a high likelihood of having an EGFR mutation; in this study, 59.7% of the tumors in a clinically selected population had EGFR mutations, as compared with 12.1% and 14.8% in the unselected populations in the ISEL and Iressa in NSCLC Trial Evaluating Response and Survival versus Taxotere (INTEREST; NCT00076388) studies, respectively.2,27
The efficacy of gefitinib seen in this study was coupled with lower incidences of alopecia, nausea, vomiting, neurotoxic symptoms, and myelosuppression than those seen with carboplatin–paclitaxel. Among 607 patients who received gefitinib and who were included in the safety analysis, interstitial-lung-disease events developed in only 16 (2.6%), 3 of whom (0.5%) died.
In summary, this study shows that first-line therapy with gefitinib as compared with carboplatin–paclitaxel prolongs progression-free survival, increases the objective response rate, and improves quality of life among clinically selected patients with non–small-cell lung cancer. The presence of an EGFR mutation was a robust predictor of improved progression-free survival with gefitinib, as compared with carboplatin–paclitaxel, and of the benefit of gefitinib with respect to the objective response rate, indicating that patients in whom an EGFR mutation has been identified will benefit most from first-line therapy with gefitinib.
Supported by AstraZeneca.
Dr. Mok reports receiving consulting fees from Roche, AstraZeneca, Pfizer, and Eli Lilly, lecture fees from Roche, AstraZeneca, and Eli Lilly, and a research grant to the Chinese Lung Cancer Research Foundation from AstraZeneca, Hong Kong; Dr. Wu, receiving consulting fees from AstraZeneca, Roche, Eli Lilly, and Pfizer and lecture fees from AstraZeneca, Roche, and Eli Lilly; Dr. Thongprasert, receiving consulting fees from AstraZeneca, Pfizer, and Sanofi-Aventis, lecture fees from AstraZeneca, Eli Lilly, and Sanofi-Aventis, and grant support from AstraZeneca, Sanofi-Aventis, and Pfizer; Dr. C.-H. Yang, receiving consulting fees and lecture fees from AstraZeneca; Dr. Saijo, owning equity in Takeda and receiving grant support from AstraZeneca, Chugai, Takeda, and Taiho; Dr. Ichinose, receiving lecture fees from Chugai, Kyowa Hakko, AstraZeneca, and Sanofi-Aventis; Dr. Ohe, receiving lecture fees from AstraZeneca, Eli Lilly, Chugai, Bristol-Myers Squibb, and Sanofi-Aventis; Dr. Chewaskulyong, receiving lecture fees from AstraZeneca and Roche; Dr. Jiang, Miss Duffield, Miss Watkins, and Dr. Armour, being salaried employees of AstraZeneca and owning equity in AstraZeneca; and Dr. Fukuoka, receiving lecture fees from AstraZeneca and Chugai. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0810699) was published on August 19, 2009, and was last updated on September 4, 2009, at NEJM.org.
We thank the patients and investigators for their participation in this study and Annette Smith, Ph.D., from Complete Medical Communications, who provided editing support funded by AstraZeneca.
Source Information
From the State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong (T.S.M.), Guangdong General Hospital, Guangzhou (Y-L.W., J.-J.Y.), Cancer Hospital, Chinese Academy of Medical Sciences, Beijing (D.-T.C.), and Shanghai Chest Hospital, Shanghai (B.H.) — all in China; Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai (S.T., B.C.), and Prince of Songkla University, Songkla (P.S.) — both in Thailand; National Taiwan University Hospital, Taipei, Taiwan (C.-H.Y.); National Cancer Center Hospital East, Chiba (N.S., Y.N.), National Kyushu Cancer Center, Fukuoka (Y.I.), National Cancer Center Hospital, Tokyo (Y.O.), AstraZeneca, Osaka (H.J.), and Kinki University School of Medicine, Osaka (M.F.) — all in Japan; Dr. Soetomo Hospital, Surabaya, Indonesia (B.M.); and AstraZeneca, Macclesfield, United Kingdom (E.L.D., C.L.W., A.A.A.).
Address reprint requests to Dr. Mok at the Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, HKSAR, China, or at tony@clo.cuhk.edu.hk.
Appendix
Members of the First Line Iressa versus Carboplatin/Paclitaxel in Asia (Iressa Pan-Asia Study [IPASS]) Study Organization were as follows: Steering Committee: T.S. Mok, M. Fukuoka, S. Thongprasert, Y.-L. Wu, C.-H. Yang, D.-T. Chu, N. Saijo, H. Jiang, C.L. Watkins, A.A. Armour (K.F. To, pathologist, advisor to steering committee). Independent Data and Safety Monitoring Committee: A. Chang, K. Eguchi, M. Buyse, S. Zuckerman. International Coordinating Investigators: T.S. Mok, M. Fukuoka. Study Personnel: S. Rigby, study coordinator and study delivery leader; H. Jiang, study physician; P. Magill, study physician; E.L. Duffield, biostatistician. Investigators: China — C. Bojun, X. Cai, X. Cai, Q. Chen, X. Chen, Y. Chen, Z. Chen, W. Cheng, X. Chongrui, D. Chu, T. Chu, J. Dai, Z. Ding, J. Duan, M. Fan, Y. Fan, J. Feng, X. Fu, M. Gao, A. Gu, J. Gu, Z. Guan, B. Han, A. Hao, Z. He, W. Hong, X. Hong, M. Hou, C. Huang, J. Huang, P. Huang, Y. Huang, Y. Huang, Y. Huang, W. Huimin, L. Jia, H. Jian, G. Jiang, L. Jiang, S. Jiao, B. Jin, M. Jin, A. Li, C. Li, H. Li, L. Li, M. Li, R. Li, T. Li, Z. Li, H. Liang, M. Liao, R. Liao, J. Liu, X. Liu, Z. Liu, F. Lou, G. Lou, S. Lu, L. Mei, Q.-Y. Meng, J. Ni, M. Oiu, H. Pan, J. Pei, L. Peng, J. Qi, M. Qi, J. Qian, H. Qiu, J. Shen, Q. Song, Y. Song, S. Sun, X. Tan, B. Wang, B. Wang, H. Wang, H. Wang, H. Wang, K. Wang, L. Wang, L. Wang, M. Wang, W. Wang, X. Wang, Y. Wang, B. Wu, Y. Wu, C. Xie, R. Xie, Y. Xin, L. Xu, Z. Xu, B. Yan, J. Yang, L. Yang, Z. Yi, S. Yu, J. Zhang, J. Zhang, L. Zhang, L. Zhang, W. Zhang, X. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, X. Zhao, Y. Zhao, W. Zhen, Z. Zhen, Y. Zheng, H. Zhong, R. Zhong, C. Zhou, Q. Zhou, T. Zhou, J. Zhu, Y. Zhu, Z. Zhu, W. Zhuang, L. Zou; Hong Kong (China) — S.K. Au, L. Chan, S. Cheung, K.-C. Chow, S.M. Chow, D. Chua, C.K. Kwan, K.C. Lam, T.C. Lam, D. Lee, R. Liu, S.H. Lo, P. Lui, T.S. Mok, P. Poon, C. Tang, K.F. To, Y.C. Tse, Y. Tung, H. Wong, M. Wong, S. Yau; Indonesia — J. Aphridasari, B. Boediwarsono, S. Endarjo, A. Febriani, H. Harijadi, A. Hudoyo, A. Kosasih, J. Kurnianda, B. Kusnan, H. Lunardhi, B. Margono, A. Mudigno, N. Nurhadi, A. Rima, K. Soedarko, C. Soeharti, J. Sugiri, M. Suprapto, E. Surjanto, E. Syahruddin, I. Tedjasukmana, P. Wibowo, K. Widayati, P. Widjanarko, L. Wulandari; Japan — Y. Akashi, K. Aoe, N. Aono, G. Asai, K. Asai, K. Asami, S. Atagi, T. Baba, K. Chikamori, H. Daga, S. Doi, M. Ebisawa, M. Endo, T. Endo, T. Fujieda, M. Fujii, S. Fujita, D. Fujiwara, S. Fukumoto, M. Fukuoka, H. Fukushima, C. Fukuyama, S. Fukuyama, S. Fukuyama, S. Fumita, K. Goto, E. Hagiwara, K. Hanioka, F. Hara, D. Harada, M. Harada, T. Harada, Y. Harada, A. Hata, Y. Hattori, M. Hayashi, S. Hibino, Y. Higashi, T. Hirano, N. Hirata, T. Hirata, T. Hishima, H. Honda, T. Horai, A. Horiike, Y. Hosomi, E. Ichihara, S. Ichihara, Y. Ichikawa, Y. Ichimaru, S. Ichinose, Y. Ichinose, S. Igawa, M. Iguchi, S. Ihara, K. Ijichi, T. Ikeda, Y. Ikezawa, Y. Imabashi, H. Imadate, Y. Imahashi, N. Imai, Y. Imai, F. Imamura, M. Inaba, T. Inoue, Y. Inoue, M. Ishida, G. Ishii, Y. Ishikawa, H. Ito, M. Ito, T. Ito, T. Iwasa, K. Iyama, S. Kajikawa, N. Kajiwara, M. Kakihana, T. Kakugawa, T. Kameya, S. Kanda, H. Kaneda, K. Kasahara, H. Kashihara, T. Kashii, K. Kashiwabara, N. Katakami, H. Katayama, N. Katayama, T. Kato, S. Kawabata, Y. Kawada, T. Kawaguchi, M. Kawahara, O. Kawai, Y. Kawai, H. Kenmotsu, Y. Kida, H. Kimura, T. Kimura, T. Kimura, E. Kin, A. Kinoshita, D. Kishino, C. Kitagawa, M. Kitaichi, A. Kitamura, K. Kitamura, M. Kitaoka, K. Kiura, H. Kiyota, S. Kobayashi, T. Kodama, T. Koga, Y. Kogure, Y. Koh, H. Kohrogi, S. Komatsu, T. Kometani, K. Komuta, A. Kubo, T. Kubo, Y. Kubo, K. Kubota, M. Kubota, K. Kudo, S. Kudo, H. Kunitoh, T. Kurata, Y. Kusunoki, S. Kyo, T. Maeda, T. Marutsuka, M. Maruyama, J. Matsubayashi, K. Matsumoto, M. Matsumoto, Y. Matsumoto, Y. Matsuno, H. Minato, S. Mitsuoka, K. Miyajima, E. Miyauchi, M. Miyazaki, T. Miyazaki, K. Mori, R. Morinaga, S. Moritani, H. Murakami, M. Murakami, T. Murakami, K. Murase, T. Nagano, S. Nagase, Y. Nagatsuka, Y. Naito, K. Nakagawa, R. Nakajima, Y. Nakamura, Y. Nakanishi, S. Nanjo, M. Nakao, M. Nara, R. Naya, S. Negoro, S. Niho, D. Niino, R. Nishihira, H. Nishimori, R. Nishimura, T. Nishimura, K. Nishino, M. Nishio, Y. Nishiwaki, K. Nishiyama, N. Nogami, H. Nokihara, M. Nomura, N. Nomura, K. Nozaki, N. Ochi, Y. Ogata, A. Ogino, T. Ogura, C. Ohbayashi, Y. Ohe, T. Ohira, H. Ohmatsu, S. Ohta, T. Ohta, F. Ohyanagi, K. Okabe, T. Okabe, I. Okamoto, K. Okamoto, S. Okamoto, T. Okamoto, W. Okamoto, T. Okamura, Y. Okano, M. Oki, K. Okishio, M. Okuno, H. Omiya, M. Omori, A. Ono, M. Osawa, A. Osoegawa, K. Otsuka, A. Oya, I. Oze, S. Saeki, N. Saijo, T. Saijo, T. Saishouji, E. Saito, H. Saito, H. Saji, H. Saka, E. Sasaki, J. Sasaki, T. Sato, T. Sato, M. Satouchi, Y. Segawa, A. Sekine, I. Sekine, R. Seo, T. Seto, M. Shibuya, T. Shimada, T. Shimokata, T. Shimokawa, T. Shinkai, T. Shinohara, H. Shirane, Y. Sogo, A. Sugawara, K. Sugi, M. Sugishita, N. Suko, M. Sumitani, T. Syukuya, M. Tabata, K. Tachibana, R. Tachikawa, H. Tada, A. Tagawa, T. Tagawa, M. Takada, S. Takada, H. Takahashi, K. Takahashi, S. Takahashi, T. Takahashi, K. Takayama, H. Takeda, K. Takeda, M. Takeda, Y. Takeshima, Y. Takeuchi, K. Takezawa, N. Takigawa, A. Tamiya, D. Tamura, T. Tamura, T. Tamura, C. Tanai, K. Tanaka, T. Tashiro, N. Teramoto, M. Terashima, Y. Tochino, S. Tokunaga, Y. Tomita, M. Tsuboi, M. Tsujimoto, K. Tsujino, Y. Tsukamoto, H. Tsukuda, M. Tsuno, J. Tsurutani, K. Tsuta, A. Tsuya, J. Uchida, O. Uchida, J. Uchino, S. Ueda, K. Uehira, K. Ueno, H. Ueoka, S. Umemura, K. Urata, S. Ushijima, J. Usuda, K. Wakasa, K. Waseda, K. Watanabe, H. Wataya, K. Yamada, I. Yamamoto, N. Yamamoto, N. Yamamoto, R. Yamamoto, Y. Yamane, K. Yamashiro, K. Yamazaki, H. Yanai, M. Yasugi, T. Yazawa, K. Yoh, T. Yoshida, M. Yoshimura, S. Yoshimura, T. Yoshinaga, K. Yumine, Y. Zen; Malaysia — A. Abdul Muttalif, N. Abdullah, H. Ahmad Zaharah, A. Awang Abdullah, J. Azizi Bin Abdul Rahman, I. Beevi, I. Hyder Ali, C.N. Choy, K.T. Chua, J. Dharmaratnam, S. Govindaraju, F.N. Lau, C.H. Leow, C.K. Liam, Y.K. Pang, S. Poosparajah, B. Rajendran, R. Raman, K. Ratnavelu, H. Sahat, V. Selvaraju, K. Sivaraman Kannan, C.K. Tiong, A. Zaatar; Philippines — A. Abelardo, F. Agustin, V. Butalid, P. Caguioa, V. Chan, G. Cornelio, D. Dizon, A. Faundo, K. Gutierez, J. Holaysan, M. Madrid, A. Malilong, A. Ong-Cornel, P. Pua, B. Ramos, E. Tan, D. Tudtud, N. Uy, A. Villalon, K. Villanueva, E. Villegas; Singapore — S.S. Leong, D. Lim, E.H. Tan, Y.O. Tan, H.K. Tan, C.K. Toh; Taiwan — T.-Y. Chao, H.-C. Chen, K.-Y. Chen, P.-J. Chen, Y.-C. Chen, Y.-M. Chen, C.-Y. Chung, C.-C. Ho, C.-L. Ho, M.-L. Ho, R.-K. Hsieh, C. Hsu, W.-Y. Kao, H.-P. Kuo, C.-H. Lai, H.-C. Lin, J.-T. Lin, M.-C. Lin, Y.-L. Lin, Z.-Z. Lin, M.-J. Peng, R.-P. Perng, J.-Y. Shih, C.-C. Wang, C.-H. Wang, J.-L. Wang, Y.-H. Wang, C.-L. Wu, C.-H. Yang, P.-C. Yang, C.-T. Yu, C.-J. Yu; Thailand — C. Akewanlop, V. Ariyaprakai, T. Ativitavas, T. Chalermchai, C. Chantranuwat, C. Charoentum, B. Chewasukulyong, T. Dudsadeeprasert, S. Geater, M. Huntrakoon, S. Juthong, N. Keerativitayanant, N. Kiatikajornthada, C. Kularbkaew, S. Laohavanij, N. Lertprasertsuke, J. Maneechavakajorn, W. Mitarnum, A. Phunmanee, P. Punyarit, M. Rochanawutanon, K. Seetalarom, E. Sirachainan, A. Sookprasert, N. Soparatanapaisarn, V. Srimuninnimit, V. Sriuranpong, P. Sunpaweravong, C. Suthipintawong, H. Suwanrusme, S. Suwanvecho, K. Thammakumpee, S. Thongprasert, V. Viriyachaiyo, N. Voravud, S. Wongbunnate.
- References
References
1
Shepherd FA ,Rodrigues Pereira J ,Ciuleanu T , et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
Full Text | Web of Science | Medline2
Kim ES ,Hirsch V ,Mok T , et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818
CrossRef | Web of Science | Medline3
Park K ,Goto K . A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006;22:561-573
CrossRef | Web of Science | Medline4
Thatcher N ,Chang A ,Parikh P , et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537
CrossRef | Web of Science | Medline5
Kosaka T ,Yatabe Y ,Endoh H ,Kuwano H ,Takahashi T ,Mitsudomi T . Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923
CrossRef | Web of Science | Medline6
Shigematsu H ,Lin L ,Takahashi T , et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346
CrossRef | Web of Science | Medline7
Lynch TJ ,Bell DW ,Sordella R , et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139
Full Text | Web of Science | Medline8
Paez JG ,Janne PA ,Lee JC , et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500
CrossRef | Web of Science | Medline9
Pao W ,Miller V ,Zakowski M , et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311
CrossRef | Web of Science | Medline10
Inoue A ,Suzuki T ,Fukuhara T , et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346
CrossRef | Web of Science | Medline11
Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361. DOI: 10.1056/NEJMoa0904554.
12
Sequist LV ,Martins RG ,Spigel D , et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449[Erratum, J Clin Oncol 2008;26:3472.]
CrossRef | Web of Science | Medline13
Chang G-C ,Chen K-C ,Yang T-Y , et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest New Drugs 2005;23:73-77
CrossRef | Web of Science | Medline14
Kimura H ,Kasahara K ,Shibata K , et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006;1:260-267
Web of Science | Medline15
Lee DH ,Han JY ,Lee HG , et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005;11:3032-3037
CrossRef | Web of Science | Medline16
Yang CH ,Yu CJ ,Shih JY , et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753
CrossRef | Web of Science | Medline17
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline18
Therasse P ,Arbuck SG ,Eisenhauer EA , et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
CrossRef | Web of Science | Medline19
Cella DF ,Bonomi AE ,Lloyd SR ,Tulsky DS ,Kaplan E ,Bonomi P . Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220
CrossRef | Web of Science | Medline20
Cella D ,Eton DT ,Fairclough DL , et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-295
CrossRef | Web of Science | Medline21
Newton CR ,Graham A ,Heptinstall LE , et al. Analysis of any point mutation in DNA: the Amplification Refractory Mutation System (ARMS). Nucleic Acids Res 1989;17:2503-2516
CrossRef | Web of Science | Medline22
Whitcombe D ,Theaker J ,Guy SP ,Brown T ,Little S . Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999;17:804-807
CrossRef | Web of Science | Medline23
Morikawa T ,Yoshida M . A useful testing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharm Stat 1995;5:297-306
CrossRef | Medline24
Westfall PH, Young SS. Resampling-based multiple testing. New York: Wiley, 1993.
25
Pfister DG ,Johnson DH ,Azzoli CG , et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353
CrossRef | Web of Science | Medline26
Schiller JH ,Harrington D ,Belani CP , et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98
Full Text | Web of Science | Medline27
Hirsch FR ,Varella-Garcia M ,Bunn PA Jr , et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042
CrossRef | Web of Science | Medline28
Tamura K ,Okamoto I ,Kashii T , et al. Multicentre prospective phase II trial of gefitinib for advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008;98:907-914
CrossRef | Web of Science | Medline29
Han S-W ,Kim T-Y ,Hwang PG , et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501
CrossRef | Web of Science | Medline30
Zhu CQ ,da Cunha SG ,Ding K , et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275
CrossRef | Web of Science | Medline31
Maheswaran S ,Sequist LV ,Nagrath S , et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377
Full Text | Web of Science | Medline
- Citing Articles (656)
Citing Articles
1
Corey A. Carter, Giuseppe Giaccone. (2012) Treatment of nonsmall cell lung cancer. Current Opinion in Oncology 24:2, 123-129
CrossRef2
Charu Aggarwal, Corey J. Langer. (2012) Older age, poor performance status and major comorbidities. Current Opinion in Oncology 24:2, 130-136
CrossRef3
Timothy A. Yap, Paul Workman. (2012) Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology 52:1, 549-573
CrossRef4
Gary J. Kelloff, Caroline C. Sigman. (2012) Cancer biomarkers: selecting the right drug for the right patient. Nature Reviews Drug Discovery
CrossRef5
T. Akiba, E. Kunieda, A. Kogawa, T. Komatsu, Y. Tamai, Y. Ohizumi. (2012) Re-irradiation for Metastatic Brain Tumors with Whole-brain Radiotherapy. Japanese Journal of Clinical Oncology
CrossRef6
Yi-long Wu, Qing Zhou. (2012) Clinical trials and biomarker research on lung cancer in China. Expert Opinion on Therapeutic Targets1-6
CrossRef7
Nagahiro Saijo. (2012) Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treatment Reviews 38:1, 63-67
CrossRef8
Yukari Tsubata, Takeshi Honda, Tamio Okimoto, Kiyotaka Miura, Fumi Karino, Shinichi Iwamoto, Taeko Suzuki, Shunichi Hamaguchi, Hibiki Kanda, Akihisa Sutani, Takashige Kuraki, Takeshi Isobe. (2012) A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and non-elderly non-small-cell lung cancer patients. Geriatrics & Gerontology Internationalno-no
CrossRef9
Ana Custodio, Míriam Méndez, Mariano Provencio. (2012) Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews 38:1, 36-53
CrossRef10
Tingting Hong, Ruxia Zhang, Dongyan Cai, Xiaohong Wu, Dong Hua. (2012) Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology 138:2, 285-291
CrossRef11
G. Somlo, C. L. Martel, S. K. Lau, P. Frankel, C. Ruel, L. Gu, A. Hurria, C. Chung, T. Luu, R. Morgan, L. Leong, M. Koczywas, M. McNamara, C. A. Russell, S. E. Kane. (2012) A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Research and Treatment 131:3, 899-906
CrossRef12
Q. Tian, N. D. Price, L. Hood. (2012) Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. Journal of Internal Medicine 271:2, 111-121
CrossRef13
Evandro Fei Fang, Clara Shui Fern Bah, Jack Ho Wong, Wen Liang Pan, Yau Sang Chan, Xiu Juan Ye, Tzi Bun Ng. (2012) A potential human hepatocellular carcinoma inhibitor from Bauhinia purpurea L. seeds: from purification to mechanism exploration. Archives of Toxicology 86:2, 293-304
CrossRef14
V. Ludovini, F. Bianconi, L. Pistola, V. Minotti, R. Chiari, R. Colella, G. Bellezza, F. R. Tofanetti, A. Siggillino, E. Baldelli, A. Flacco, D. Giuffrida, A. Sidoni, L. Crinò. (2012) Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemotherapy and Pharmacology
CrossRef15
Janet E. Dancey, Philippe L. Bedard, Nicole Onetto, Thomas J. Hudson. (2012) The Genetic Basis for Cancer Treatment Decisions. Cell 148:3, 409-420
CrossRef16
M. Falk, C. Hallas, M. Tiemann. (2012) Molekularpathologische Grundlagen für die Therapie des NSCLC. best practice onkologie 7:1, 4-11
CrossRef17
Mathew J. Garnett, Ultan McDermott. (2012) Exploiting genetic complexity in cancer to improve therapeutic strategies. Drug Discovery Today
CrossRef18
J. De Grève, E. Teugels, C. Geers, L. Decoster, D. Galdermans, J. De Mey, H. Everaert, I. Umelo, P. In’t Veld, D. Schallier. (2012) Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer
CrossRef19
Liang Cheng, Riley E Alexander, Gregory T MacLennan, Oscar W Cummings, Rodolfo Montironi, Antonio Lopez-Beltran, Harvey M Cramer, Darrell D Davidson, Shaobo Zhang. (2012) Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology
CrossRef20
Takashi Kobayashi, Tomonobu Koizumi, Toshihide Agatsuma, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Seiichiro Eda, Hiroshi Kuraishi, Shigeru Koyama, Tsutomu Hachiya, Nariaki Ohura. (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef21
M L Sos, R K Thomas. (2012) Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene
CrossRef22
H.E. Gabbert, T. Kirchner. (2012) Prädiktive Biomarker als Entscheidungsgrundlage für die onkologische Therapie. Forum
CrossRef23
Alexander Kühn, Hans Lehrach. (2012) The “Virtual Patient” system: modeling cancer using deep sequencing technologies for personalized cancer treatment. Journal für Verbraucherschutz und Lebensmittelsicherheit
CrossRef24
T Doi, H Takiuchi, A Ohtsu, N Fuse, M Goto, M Yoshida, N Dote, Y Kuze, F Jinno, M Fujimoto, T Takubo, N Nakayama, R Tsutsumi. (2012) Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. British Journal of Cancer
CrossRef25
2012. References. , 311-327.
CrossRef26
R.M. Huber, A. Tufmann. (2012) Diagnostik und Staging beim fortgeschrittenen Lungenkarzinom. Der Pneumologe
CrossRef27
M. Knopf, M. Reck. (2012) Erstlinientherapie beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom. Der Pneumologe
CrossRef28
Parthasarathy Seshacharyulu, Moorthy P Ponnusamy, Dhanya Haridas, Maneesh Jain, Apar K Ganti, Surinder K Batra. (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets 16:1, 15-31
CrossRef29
Athanasios G. Pallis, Kostas Syrigos. (2012) Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. Cancer Treatment Reviews
CrossRef30
M.E.R. O’Brien, J.S. Myerson, J.I.G. Coward, M. Puglisi, L. Trani, A. Wotherspoon, B. Sharma, G. Cook, S. Ashley, R. Gunapala, S. Chua, S. Popat. (2012) A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks. European Journal of Cancer 48:1, 68-74
CrossRef31
Mathilda L. Bongers, Veerle M.H. Coupé, Elise P. Jansma, Egbert F. Smit, Carin A. Uyl-de Groot. (2012) Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics 30:1, 17-34
CrossRef32
Sai-Hong Ignatius Ou. (2012) Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology
CrossRef33
Koichi Goto, Yukito Ichinose, Yuichiro Ohe, Nobuyuki Yamamoto, Shunichi Negoro, Kazuto Nishio, Yohji Itoh, Haiyi Jiang, Emma Duffield, Rose McCormack, Nagahiro Saijo, Tony Mok, Masahiro Fukuoka. (2012) Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum. Journal of Thoracic Oncology 7:1, 115-121
CrossRef34
Mitchell E. Gross, Lawrence Leichman, Elizabeth S. Lowe, Alan Swaisland, David B. Agus. (2012) Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology 69:1, 273-280
CrossRef35
Alexandra F. Leary, David Gonzalez de Castro, Andrew G. Nicholson, Sue Ashley, Andrew Wotherspoon, Mary E.R. O’Brien, Sanjay Popat. (2012) Establishing an EGFR mutation screening service for non-small cell lung cancer – Sample quality criteria and candidate histological predictors. European Journal of Cancer 48:1, 61-67
CrossRef36
William Dubinski, Natasha B. Leighl, Ming-Sound Tsao, David M. Hwang. (2012) Ancillary Testing in Lung Cancer Diagnosis. Pulmonary Medicine 2012, 1-8
CrossRef37
Shunsuke Okumura, Takaaki Sasaki, Yoshinori Minami, Yoshinobu Ohsaki. (2012) Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation. Journal of Thoracic Oncology 7:1, 49-56
CrossRef38
ETIENNE GIROUX LEPRIEUR, ARMELLE LAVOLE, ANNE-MARIE RUPPERT, VALéRIE GOUNANT, MARIE WISLEZ, JACQUES CADRANEL, BERNARD MILLERON. (2012) Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology 17:1, 134-142
CrossRef39
Betty C. Tong, David H. Harpole. (2012) Molecular Markers for Incidence, Prognosis, and Response to Therapy. Surgical Oncology Clinics of North America 21:1, 161-175
CrossRef40
Hee Seok Lee, Jun Won Park, Oleg Chertov, Simona Colantonio, John T. Simpson, Matthew J. Fivash, Chong Woo Yoo, Geon Kook Lee, Jae Ill Zo, Heung Tae Kim, Hark Kyun Kim. (2012) Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer. Pathology International 62:1, 28-35
CrossRef41
Janakiraman Subramanian, Saiama N. Waqar, Daniel Morgensztern, Ramaswamy Govindan. (2012) Recent Advances in Lung Cancer. Journal of Thoracic Oncology 7:1, 260-265
CrossRef42
Shang-Gin Wu, Yao-Wen Kuo, Yih-Leong Chang, Jin-Yuan Shih, Ya-Hui Chen, Meng-Feng Tsai, Chong-Jen Yu, Chih-Hsin Yang, Pan-Chyr Yang. (2012) EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. Journal of Thoracic Oncology 7:1, 98-104
CrossRef43
Chiara Lazzari, Anna Spreafico, Angela Bachi, Heinrich Roder, Irene Floriani, Daniela Garavaglia, Angela Cattaneo, Julia Grigorieva, Maria Grazia Viganò, Cristina Sorlini, Domenico Ghio, Maxim Tsypin, Alessandra Bulotta, Luca Bergamaschi, Vanesa Gregorc. (2012) Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology 7:1, 40-48
CrossRef44
Fu-Tsai Chung, Kang-Yun Lee, Chih-Wei Wang, Chih-Chen Heh, Yao-Fei Chan, Huan-Wu Chen, Chih-Hsi Kuo, Po-Hao Feng, Ting-Yu Lin, Chun-Hua Wang, Chun-Liang Chou, Hao-Cheng Chen, Shu-Min Lin, Han-Pin Kuo. (2012) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. International Journal of Cancern/a-n/a
CrossRef45
Cheng-Bo Han, Jie-Tao Ma, Fan Li, Jian-Zhu Zhao, Wei Jing, Yang Zhou, Hua-Wei Zou. (2012) EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. Cancer Letters 314:1, 63-72
CrossRef46
Aya Tanaka, Naoko Sueoka-Aragane, Tomomi Nakamura, Yuji Takeda, Masahiro Mitsuoka, Fumio Yamasaki, Shinichiro Hayashi, Eisaburo Sueoka, Shinya Kimura. (2012) Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 75:1, 89-94
CrossRef47
Seung Tae Kim, Ji Eun Uhm, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2012) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75:1, 82-88
CrossRef48
Haihua Yuan, Zhong-Zheng Zhu, Yachao Lu, Feng Liu, Wenying Zhang, Gang Huang, Guanshan Zhu, Bin Jiang. (2012) A Modified Extraction Method of Circulating Free DNA for Epidermal Growth Factor Receptor Mutation Analysis. Yonsei Medical Journal 53:1, 132
CrossRef49
Jared Weiss, Thomas E Stinchcombe. (2012) Treatment of elderly patients with stage IV non-small-cell lung cancer. Expert Review of Anticancer Therapy 12:1, 111-120
CrossRef50
Koichi Azuma, Isamu Okamoto, Akihiko Kawahara, Tomoki Taira, Kazutaka Nakashima, Satoshi Hattori, Takashi Kinoshita, Masayuki Takeda, Kazuhiko Nakagawa, Shinzo Takamori, Michihiko Kuwano, Mayumi Ono, Masayoshi Kage. (2012) Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment. Journal of Thoracic Oncology 7:1, 122-127
CrossRef51
Hiroyuki Yasuda, Susumu Kobayashi, Daniel B Costa. (2012) EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. The Lancet Oncology 13:1, e23-e31
CrossRef52
Luis Paz-Ares. (2012) Beyond first-line NSCLC therapy: chemotherapy or erlotinib?. The Lancet Oncology
CrossRef53
Ramaswamy Govindan, Janakiraman Subramanian. (2012) Optimising therapy for EGFR-addicted NSCLC: just the start. The Lancet Oncology
CrossRef54
Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee A. Maxson, Andrew J. Weickhardt, Ana B. Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella-Garcia, D. Ross Camidge. (2012) Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancern/a-n/a
CrossRef55
Alexandra V. Lucs, Benjamin Saltman, Christine H. Chung, Bettie M. Steinberg, David L. Schwartz, Jeffrey N. Myers. (2012) Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. Head & Neckn/a-n/a
CrossRef56
Wolfram Brugger, Michael Thomas. (2012) EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment. Lung Cancer
CrossRef57
Corey J. Langer. (2012) Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges. Critical Reviews in Oncology/Hematology
CrossRef58
Lourdes Cucurull-Sanchez, Karen G. Spink, Sterghios Athanasios Moschos. (2012) Relevance of systems pharmacology in drug discovery. Drug Discovery Today
CrossRef59
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier de Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology
CrossRef60
Young Hak Kim, Shinji Sumiyoshi, Seiji Hashimoto, Katsuhiro Masago, Yosuke Togashi, Yuichi Sakamori, Chiyuki Okuda, Tadashi Mio, Michiaki Mishima. (2012) Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef61
Takanori Ayabe, Tetsuya Shimizu, Masaki Tomita, Masaki Hara, Toshio Onitsuka. (2012) A case of long-term survival of gefitinib-induction therapy for advanced N2-multistation lung cancer without epidermal growth factor receptor gene mutation. Annals of Cancer Research and Therapy 19:2, 62-65
CrossRef62
Gopa Iyer, Matthew I. Milowsky. (2012) Fibroblast growth factor receptor-3 in urothelial tumorigenesis
. Urologic Oncology: Seminars and Original Investigations
CrossRef63
Ricardo González-Cámpora. (2012) Consenso Nacional SEAP-SEOM sobre biomarcadores en el cáncer de pulmón no microcítico avanzado. Revista Española de Patología
CrossRef64
José Javier Gómez, Javier de Castro, Ángel Concha, Enriqueta Felip, Dolores Isla, Fernando López-Ríos, Luis Paz-Ares, José Ramírez, Julián Sanz, Pilar Garrido. (2012) Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Revista Española de Patología
CrossRef65
Roman Thomas, Jürgen Wolf. (2012) Personalized Therapy of Lung Cancer. Onkologie 35:s1, 14-19
CrossRef66
Haruhiro Saito, Haruhiro Saito, Shuji Murakami, Shuji Murakami, Tetsuro Kondo, Tetsuro Kondo, Fumihiro Oshita, Fumihiro Oshita, Kazumasa Noda, Kazumasa Noda, Kouzo Yamada, Kouzo Yamada. (2012) Effectiveness of Erlotinib in Advanced Non-Small Cell Lung Cancer in Cases of Gefitinib Resistance after Treatment of More Than 6 Months. Onkologie 35:1-2, 18-22
CrossRef67
Wolf-Dieter Ludwig. (2012) Möglichkeiten und Grenzen der stratifizierenden Medizin am Beispiel von prädiktiven Biomarkern und „zielgerichteten“ medikamentösen Therapien in der Onkologie. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
CrossRef68
M. Pless. (2011) Das fortgeschrittene Lungenkarzinom. Der Pneumologe
CrossRef69
R. Vijayalakshmi, Arvind Krishnamurthy. (2011) Targetable “Driver” Mutations in Non Small Cell Lung Cancer. Indian Journal of Surgical Oncology
CrossRef70
Hang Zhu, Hua Cheng, Yuan Ren, Zhan Guo Liu, Yi Fang Zhang, Bing Luo. (2011) Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Molecular Biology Reports
CrossRef71
Sinchita Roy Chowdhuri, Liqiang Xi, Trinh Hoc-Tran Pham, Jeffrey Hanson, Jaime Rodriguez-Canales, Arlene Berman, Arun Rajan, Giuseppe Giaccone, Michael Emmert-Buck, Mark Raffeld, Armando C Filie. (2011) EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Modern Pathology
CrossRef72
M J Fidler, L E Morrison, S Basu, L Buckingham, K Walters, M Batus, K K Jacobson, S S Jewell, J Coon, P D Bonomi. (2011) PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. British Journal of Cancer 105:12, 1920-1926
CrossRef73
Manish R. Sharma, Richard L. Schilsky. (2011) Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews Clinical Oncology
CrossRef74
Shannon M. Mumenthaler, Jasmine Foo, Kevin Leder, Nathan C. Choi, David B. Agus, William Pao, Parag Mallick, Franziska Michor. (2011) Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Molecular Pharmaceutics 8:6, 2069-2079
CrossRef75
Benjamin Besse, David Planchard, Anne-Sophie Veillard, Laurent Taillade, David Khayat, Muriel Ducourtieux, Jean-Pierre Pignon, Jean Lumbroso, Carole Lafontaine, Claire Mathiot, Jean-Charles Soria. (2011) Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer
CrossRef76
Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari. (2011) Hematologic toxicities of small molecule tyrosine kinase inhibitors. Targeted Oncology 6:4, 203-215
CrossRef77
Peter Keating, Alberto Cambrosio. (2011) Clinical trials in the age of personalized medicine. Journal of Medicine and the Person 9:3, 91-98
CrossRef78
Scott Gettinger, Thomas Lynch. (2011) A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest Medicine 32:4, 839-851
CrossRef79
Hidenori Fukuoka, Odelia Cooper, Anat Ben-Shlomo, Adam Mamelak, Song-Guang Ren, Dave Bruyette, Shlomo Melmed. (2011) EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. Journal of Clinical Investigation 121:12, 4712-4721
CrossRef80
Cesare Gridelli, Andrea Ardizzoni, Sandro Barni, Lucio Crinò, Alberto Caprioli, Elena Piazza, Vito Lorusso, Santi Barbera, Nicoletta Zilembo, Vittorio Gebbia, Vincenzo Adamo, Riccardo Pela, Maurizio Marangolo, Raffaella Morena, Gianfranco Filippelli, Calogero Buscarino, Oscar Alabiso, Paolo Maione, Paola Venturino, Filippo De Marinis. (2011) Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study. Lung Cancer 74:3, 462-468
CrossRef81
Frauke Müller, Hendrik Riesenberg, Peter Hirnle, Hans-Björn Gehl, Paul Düwel, Martin Görner. (2011) Komplette Remission multifokaler zerebraler Metastasen bei chemotherapierefraktärem NSCLC durch Monotherapie mit Gefitinib. Strahlentherapie und Onkologie 187:12, 826-830
CrossRef82
Fang Wang, Gui-fang Guo, Hui-juan Qiu, Xu-xian Chen, Pi-li Hu, Fei-fei Zhou, Wen-zhuo He, Bei Zhang, Liang-ping Xia. (2011) Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. Clinical Oncology and Cancer Research 8:4, 235-241
CrossRef83
M. Fiegl, C. Thöni, M. Hochleitner. (2011) Gender aspects in haematology and oncology: Overview and own observations in lung cancer. memo - Magazine of European Medical Oncology 4:4, 209-216
CrossRef84
Tetsuhiko Taira, Genichiro Ishii, Kanji Nagai, Kiyotaka Yoh, Yusuke Takahashi, Yuki Matsumura, Motohiro Kojima, Hironobu Ohmatsu, Koichi Goto, Seiji Niho, Hiroshi Takashima, Hiromasa Inoue, Yuichiro Ohe, Atsushi Ochiai. (2011) Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. Lung Cancer
CrossRef85
Jair Bar, Amir Onn. (2011) Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer
CrossRef86
Liang-Ping Xia, Hui-Juan Qiu, Xu-Xian Chen, Pi-Li Hu, Gui-Fang Guo, Fang Wang, Fei-Fei Zhou, Wen-Zhuo He, Bei Zhang, Li Zhang. (2011) Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. Medical Oncology 28:S1, 570-576
CrossRef87
H Li, G Schmid-Bindert, D Wang, Y Zhao, X Yang, B Su, C Zhou. (2011) Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines. Advances in Medical Sciences 56:2, 275-284
CrossRef88
Geoffrey Y. Ku, Benjamin A. Haaland, Gilberto de Lima Lopes. (2011) Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials. Lung Cancer 74:3, 469-473
CrossRef89
Martin Filipits, Robert Pirker. (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74:3, 355-363
CrossRef90
Nicholas A. Barber, Apar Kishor Ganti. (2011) Pulmonary toxicities from targeted therapies: a review. Targeted Oncology 6:4, 235-243
CrossRef91
Sabita Jiwnani, George Karimundackal, C.S. Pramesh, Kumar Prabhash. (2011) What is the true prevalence of EGFR mutations in India?. Lung Cancer 74:3, 549
CrossRef92
Pek Keng Koh, Corinne Faivre-Finn, Fiona H. Blackhall, Dirk De Ruysscher. (2011) Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treatment Reviews
CrossRef93
Erik Thunnissen, Keith M. Kerr, Felix J.F. Herth, Sylvie Lantuejoul, Mauro Papotti, Robert C. Rintoul, Giulio Rossi, Birgit G. Skov, Birgit Weynand, Lukas Bubendorf, Grünberg Katrien, Leif Johansson, Fernando López-Ríos, Vincent Ninane, Włodzimierz Olszewski, Helmut Popper, Sauleda Jaume, Philipp Schnabel, Luc Thiberville, Florian Laenger. (2011) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer
CrossRef94
Laura Bonanno, Adolfo Favaretto, Massimo Rugge, Miquel Taron, Rafael Rosell. (2011) Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs 71:17, 2231-2246
CrossRef95
Thanyanan Reungwetwattana, Saravut J. Weroha, Julian R. Molina. (2011) Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC). Clinical Lung Cancer
CrossRef96
William D. Travis. (2011) Pathology of Lung Cancer. Clinics in Chest Medicine 32:4, 669-692
CrossRef97
A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, R. Tachikawa, K. Tomii, Y. Imai, M. Iwasaku, T. Ishida. (2011) Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients. Japanese Journal of Clinical Oncology 41:12, 1366-1372
CrossRef98
Paul Mitchell, Tony Mok, Helen Barraclough, Alena Strizek, Rebecca Lew, Maximiliano van Kooten. (2011) Smoking History As a Predictive Factor of Treatment Response in Advanced Non–Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer
CrossRef99
Vikram K. Jain, Eliza A. Hawkes, David Cunningham. (2011) Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 10:4, 245-257
CrossRef100
Jin Hyun Park, Yu Jung Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jin-Haeng Chung, Jae Sung Kim, Jong Seok Lee. (2011) Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer
CrossRef101
Takehito Shukuya, Toshiaki Takahashi, Tateaki Naito, Rieko Kaira, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Hirotsugu Kenmotsu, Haruyasu Murakami, Hideyuki Harada, Koichi Mitsuya, Masahiro Endo, Yoko Nakasu, Kazuhisa Takahashi, Nobuyuki Yamamoto. (2011) Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 74:3, 457-461
CrossRef102
Jiri Horak, Jeff White, Adrian L. Harris, Mark Verrill, James Carmichael, Alison Holt, Mireille Cantarini, Merran Macpherson, Alan Swaisland, Helen Swaisland, Chris Twelves. (2011) The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology 68:6, 1485-1495
CrossRef103
Seiji Yano, Tadaaki Yamada, Shinji Takeuchi, Keisei Tachibana, Yuko Minami, Yasushi Yatabe, Tetsuya Mitsudomi, Hidenori Tanaka, Tatsuo Kimura, Shinzoh Kudoh, Hiroshi Nokihara, Yuichiro Ohe, Jun Yokota, Hidetaka Uramoto, Kosei Yasumoto, Katsuyuki Kiura, Masahiko Higashiyama, Makoto Oda, Haruhiro Saito, Junji Yoshida, Kazuya Kondoh, Masayuki Noguchi. (2011) Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. Journal of Thoracic Oncology 6:12, 2011-2017
CrossRef104
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, I. T. Lennes, S. Digumarthy, B. A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, S. B. Goldberg, J. Gainor, C. L. Channick, J. C. Wain, H. Gaissert, D. M. Donahue, A. Muniappan, C. Wright, H. Willers, D. J. Mathisen, N. C. Choi, J. Baselga, T. J. Lynch, L. W. Ellisen, M. Mino-Kenudson, M. Lanuti, D. R. Borger, A. J. Iafrate, J. A. Engelman, D. Dias-Santagata. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology 22:12, 2616-2624
CrossRef105
Isabel Bover, Christian Rolfo, Eloisa Jantus-Lewintre, Rafael Sirera, Carlos Camps, Imane Chaib, Jose L. Ramirez-Serrano, Susana Benlloch, Miguel Angel Molina-Vila, Sara Simonetti, Carlota Costa, Ana Gimenez-Capitan, Pedro Mendez, Miguel Taron, Rafael Rosell. (2011) Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop. Lung Cancer 74:3, 535-543
CrossRef106
Nichole T. Tanner, Nicholas J. Pastis, Carol Sherman, George R. Simon, David Lewin, Gerard A. Silvestri. (2011) The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer
CrossRef107
, H. Popper, F. Wrba, U. Gruber-Mösenbacher, W. Hulla, R. Pirker, W. Hilbe, M. Studnicka, A. Mohn-Staudner, F. Ploner. (2011) A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)–in non-small-cell lung cancer (NSCLC)*. memo - Magazine of European Medical Oncology 4:4, 248-253
CrossRef108
Ákos Végvári, Balázs Döme. (2011) State-of-the-art MS technology applications in lung disease. Bioanalysis 3:23, 2665-2677
CrossRef109
Jane L. Hurwitz, Izabela Stasik, Emma M. Kerr, Caitriona Holohan, Kelly M. Redmond, Kirsty M. McLaughlin, Sara Busacca, Dario Barbone, V. Courtney Broaddus, Steven G. Gray, Ken J. O’Byrne, Patrick G. Johnston, Dean A. Fennell, Daniel B. Longley. (2011) Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. European Journal of Cancer
CrossRef110
W. Berger, A. Pircher, M. Sibilia, L. Bubendorf, M. Filipits, M. Fiegl, M. Früh, C. Manegold, H. Popper, W. Hilbe. (2011) Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras–Raf–MEK–ERK pathway. memo - Magazine of European Medical Oncology 4:4, 242-247
CrossRef111
W. Jeffrey Petty, William R. Voelzke, James J. Urbanic, Victor A. Varela, Lynsay L. Waller, Catherine B. Swift, R. Matthew Graham, Vincent A. Memoli, Konstantin H. Dragnev. (2011) High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer 74:3, 384-391
CrossRef112
Randeep Sangha, Angela M. Davies, Primo N. Lara, Philip C. Mack, Laurel A. Beckett, Paul J. Hesketh, Derick Lau, Tianhong Li, Natasha Perkins, David R. Gandara. (2011) Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation. Journal of Thoracic Oncology 6:12, 2112-2119
CrossRef113
M.J. Lind. (2011) Principles of cytotoxic chemotherapy. Medicine 39:12, 711-716
CrossRef114
Jan Nyrop Jakobsen, Jens Benn Sørensen. (2011) Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef115
Rodrigo Dienstmann, Sara De Dosso, Enriqueta Felip, Josep Tabernero. (2011) Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Molecular Oncology
CrossRef116
P. Hofman, M. Ilie, V. Hofman, S. Roux, A. Valent, A. Bernheim, M. Alifano, F. Leroy-Ladurie, F. Vaylet, I. Rouquette, P. Validire, M. Beau-Faller, L. Lacroix, J. C. Soria, P. Fouret. (2011) Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Annals of Oncology
CrossRef117
Shuang Zhang, Hongwei Tian, Qingyuan Jiang, Li Li, Yu Ding, Lei Dai, Yu Xiang, Guobo Shen, Lin Cheng, Qiaorong Huang, Yalin Liu, Xiaomei Zhang, Yongping Ma, Na Zhang, Shengyong Liu, Wei Wang, Lixia Dai, Yiming Li, Xia Zhao, Yuquan Wei, Hongxin Deng. (2011) Suppression of Epidermal Growth Factor Receptor (EGFR) Expression by Small Hairpin RNA Inhibits the Growth of Human Nonsmall Cell Lung Cancers Bearing Wild-type and Mutant EGFR. Cancer Investigation 29:10, 701-708
CrossRef118
Giampietro Gasparini, Raffaele Longo. (2011) The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets1-10
CrossRef119
Haiping Zhang, Xiongwei Zheng, Tianhai Ji, Li Fu, Dongyu Bai, Yongqiang Liao, Haifang Zhang, Yi Ding, Limou Zheng. (2011) Comparative Screening of K-ras Mutations in Colorectal Cancer and Lung Cancer Patients Using a Novel Real-Time PCR with ADx-K-ras Kit and Sanger DNA Sequencing. Cell Biochemistry and Biophysics
CrossRef120
Joaquim Bosch-Barrera, Nuria Quer, Joan Brunet. (2011) Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. Clinical Lung Cancer 12:6, 335-340
CrossRef121
Peter Mazzone, Tarek Mekhail. (2011) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine
CrossRef122
Vijay Agarwal, Michael J. Lind, Lynn Cawkwell. (2011) Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews 37:7, 533-542
CrossRef123
Ji Hye Min, Ho Yun Lee, Hoyeong Lim, Myung-Ju Ahn, Keunchil Park, Man Pyo Chung, Kyung Soo Lee. (2011) Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemotherapy and Pharmacology 68:5, 1099-1109
CrossRef124
Nathan A. Pennell. (2011) Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non–Small-cell Lung Cancer. Clinical Lung Cancer 12:6, 350-359
CrossRef125
Ezra E.W. Cohen, Janakiraman Subramanian, Feng Gao, Livia Szeto, Mark Kozloff, Leonardo Faoro, Theodore Karrison, Ravi Salgia, Ramaswamy Govindan, Everett E. Vokes. (2011) Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer
CrossRef126
Fausto Petrelli, Karen Borgonovo, Mary Cabiddu, Sandro Barni. (2011) Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 22:10, 1010-1019
CrossRef127
Humberto Lara-Guerra, Catherine T. Chung, Joerg Schwock, Melania Pintilie, David M. Hwang, Natasha B. Leighl, Thomas K. Waddell, Ming-Sound Tsao. (2011) Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer
CrossRef128
Tommaso De Pas, Francesca Toffalorio, Michela Manzotti, Caterina Fumagalli, Gianluca Spitaleri, Chiara Catania, Angelo Delmonte, Monica Giovannini, Lorenzo Spaggiari, Filippo de Braud, Massimo Barberis. (2011) Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology 6:11, 1895-1901
CrossRef129
Armida D'Incecco, Federico Cappuzzo. (2011) Gefitinib for non-small-cell lung cancer treatment. Expert Opinion on Drug Safety 10:6, 987-996
CrossRef130
Ji-Youn Han, Jin Young Kim, Suk Hyung Lee, Nam Jin Yoo, Byung Gil Choi. (2011) Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer 74:2, 293-299
CrossRef131
Jean-Charles Soria, Tony S. Mok, Federico Cappuzzo, Pasi A. Jänne. (2011) EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews
CrossRef132
Gary M. Clark. (2011) Biostatistical Considerations in Development of Biomarker-Based Tests to Guide Treatment Decisions. Statistics in Biopharmaceutical Research 3:4, 549-560
CrossRef133
Hye-Suk Han, Dae-Woon Eom, Joo Heon Kim, Kyung-Hee Kim, Hyang-Mi Shin, Jin Young An, Ki Man Lee, Kang Hyeon Choe, Ki Hyeong Lee, Seung Taik Kim, Ji Hae Koo, Ho-chang Lee, Ok-Jun Lee. (2011) EGFR Mutation Status in Primary Lung Adenocarcinomas and Corresponding Metastatic Lesions: Discordance in Pleural Metastases. Clinical Lung Cancer 12:6, 380-386
CrossRef134
Y. Naito, K. Kubota, H. Ohmatsu, K. Goto, S. Niho, K. Yoh, Y. Ohe. (2011) Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Annals of Oncology 22:11, 2471-2475
CrossRef135
Georg Holgersson, Stefan Bergström, Michael Bergqvist, Jan Nyman, Even Hoye, Martin Helsing, Signe Friesland, Margareta Holgersson, Elisabet Birath, Simon Ekman, Thomas Blystad, Sven-Börje Ewers, Charlotte Mörth, Britta Löden, Roger Henriksson. (2011) Swedish Lung Cancer Radiation Study Group: Predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. European Journal of Cancer 47:16, 2415-2421
CrossRef136
Kenichi Suda, Kenji Tomizawa, Hirotaka Osada, Yoshihiko Maehara, Yasushi Yatabe, Yoshitaka Sekido, Tetsuya Mitsudomi. (2011) Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer
CrossRef137
Britta Weber, Boe S. Sorensen, Marianne Marquard Knap, Hans Henrik Madsen, Ebba Nexo, Peter Meldgaard. (2011) Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. Journal of Thoracic Oncology 6:11, 1946-1949
CrossRef138
Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances A Shepherd. (2011) Non-small-cell lung cancer. The Lancet 378:9804, 1727-1740
CrossRef139
Chee-Hong Lee, Chong-Kin Liam, Yong-Kek Pang, Keong-Tiong Chua, Boon-Khaw Lim, Nai-Lang Lai. (2011) Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. Lung Cancer 74:2, 349-351
CrossRef140
Julie A. Keating, Rob Striker. (2011) Phosphorylation events during viral infections provide potential therapeutic targets. Reviews in Medical Virologyn/a-n/a
CrossRef141
Carlie S. Sigel, Andre L. Moreira, William D. Travis, Maureen F. Zakowski, Raymond H. Thornton, Gregory J. Riely, Natasha Rekhtman. (2011) Subtyping of Non-small Cell Lung Carcinoma. Journal of Thoracic Oncology 6:11, 1849-1856
CrossRef142
A. Becker, L. Crombag, D.A.M. Heideman, F.B. Thunnissen, A.W. van Wijk, P.E. Postmus, E.F. Smit. (2011) Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. European Journal of Cancer 47:17, 2603-2606
CrossRef143
Richard L Schilsky. (2011) Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine 8:6, 633-640
CrossRef144
Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, Yi-Long Wu, James Chih-Hsin Yang, Da-Tong Chu, Meilin Liao, Yuh-Min Chen, Han-Pin Kuo, Shunichi Negoro, Kwok Chi Lam, Alison Armour, Patrick Magill, Masahiro Fukuoka. (2011) Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS). Journal of Thoracic Oncology 6:11, 1872-1880
CrossRef145
Jin Ho Paik, Chang-Min Choi, Hyojin Kim, Se Jin Jang, Gheeyoung Choe, Dong Kwan Kim, Hwa Jung Kim, Hoil Yoon, Choon-Taek Lee, Sanghoon Jheon, Ji-Young Choe, Jin-Haeng Chung. (2011) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer. Lung Cancer
CrossRef146
Akshay Sudhindra, Roberto Ochoa, Edgardo S. Santos. (2011) Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer 12:6, 360-368
CrossRef147
Kazuhiro Asami, Tomonobu Koizumi, Kazuya Hirai, Shingo Ameshima, Akihiro Tsukadaira, Nobutoshi Morozumi, Akio Morikawa, Shinji Atagi, Masaaki Kawahara. (2011) Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study. Clinical Lung Cancer 12:6, 387-392
CrossRef148
Chengbo Han, Jietao Ma, Jianzhu Zhao, Yang Zhou, Wei Jing, Huawei Zou. (2011) EGFR Mutations, Gene Amplification, and Protein Expression and KRAS Mutations in Primary and Metastatic Tumors of Nonsmall Cell Lung Cancers and Their Clinical Implications: A Meta-Analysis. Cancer Investigation 29:9, 626-634
CrossRef149
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Lanuti, Michael, Sequist, Lecia V., Sharma, Amita, Mino-Kenudson, Mari, . (2011) Case 31-2011. New England Journal of Medicine 365:15, 1426-1435
Full Text150
A Horiike, K Kudo, E Miyauchi, F Ohyanagi, K Kasahara, T Horai, M Nishio. (2011) Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British Journal of Cancer 105:8, 1131-1136
CrossRef151
P. T. Tran, P. K. Bendapudi, H. J. Lin, P. Choi, S. Koh, J. Chen, G. Horng, N. P. Hughes, L. H. Schwartz, V. A. Miller, T. Kawashima, T. Kitamura, D. Paik, D. W. Felsher. (2011) Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation. Science Translational Medicine 3:103, 103ra99-103ra99
CrossRef152
Katy R. Linskey, Dora Dias-Santagata, Rosalynn M. Nazarian, Long P. Le, Quynh Lam, Kirsten S.W. Bellucci, Leslie Robinson-Bostom, Martin C. Mihm, Mai P. Hoang. (2011) Malignant Neurocristic Hamartoma. The American Journal of Surgical Pathology 35:10, 1570-1577
CrossRef153
Frances A. Shepherd, Jean-Yves Douillard, George R. Blumenschein. (2011) Immunotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:10, 1763-1773
CrossRef154
Yosuke Togashi, Katsuhiro Masago, Shiro Fujita, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Young Hak Kim, Tadashi Mio, Michiaki Mishima. (2011) Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer 74:1, 98-102
CrossRef155
A.-B. Cortot. (2011) Actualités en oncologie thoracique. Revue des Maladies Respiratoires Actualités 3:5, 515-518
CrossRef156
Andreas Mauerer, Eva Herschberger, Wolfgang Dietmaier, Michael Landthaler, Christian Hafner. (2011) Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. Experimental Dermatology 20:10, 848-850
CrossRef157
Edward D. Blair, James A. Blakemore. (2011) Drug–diagnostic co-development: how to harness the value. Drug Discovery Today 16:19-20, 902-905
CrossRef158
S. Rivera, L. Quéro, S. Wong Hee Kam, C. Maylin, É. Deutsch, C. Hennequin. (2011) Thérapies ciblées et radiothérapie dans les cancers bronchiques non à petites cellules. Cancer/Radiothérapie 15:6-7, 527-535
CrossRef159
Szilvia Torok, Balazs Hegedus, Viktoria Laszlo, Mir Alireza Hoda, Bahil Ghanim, Walter Berger, Walter Klepetko, Balazs Dome, Gyula Ostoros. (2011) Lung cancer in never smokers. Future Oncology 7:10, 1195-1211
CrossRef160
Alice T Shaw, Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney, Ravi Salgia, Robert G Maki, Marileila Varella-Garcia, Robert C Doebele, Yung-Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, A John Iafrate, D Ross Camidge. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet Oncology 12:11, 1004-1012
CrossRef161
Martin Reck, Andreas Hermes, Eng-Huat Tan, Enriqueta Felip, Barbara Klughammer, José Baselga. (2011) Tissue sampling in lung cancer: A review in light of the MERIT experience. Lung Cancer 74:1, 1-6
CrossRef162
Tomomi Nakamura, Naoko Sueoka-Aragane, Kentaro Iwanaga, Akemi Sato, Kazutoshi Komiya, Tomonori Abe, Norio Ureshino, Shinichiro Hayashi, Toshiya Hosomi, Mitsuharu Hirai, Eisaburo Sueoka, Shinya Kimura. (2011) A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA. Journal of Thoracic Oncology 6:10, 1639-1648
CrossRef163
Athanasios G. Pallis, Alexandra Voutsina, Nikolaos Kentepozidis, Stylianos Giassas, Pavlos Papakotoulas, Sofia Agelaki, Kostas Tryfonidis, Athanasios Kotsakis, Lambros Vamvakas, Nikolaos Vardakis, Vassilis Georgoulias. (2011) A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef164
Hui-li Wong, Richard H de Boer. (2011) Vandetanib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 12:14, 2271-2278
CrossRef165
Hyo Sup Shim, Da Hye Lee, Eun Ju Park, Se Hoon Kim. (2011) Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification. Archives of Pathology & Laboratory Medicine 135:10, 1329-1334
CrossRef166
Robert Pirker, Martin Filipits. (2011) Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology/Hematology 80:1, 1-9
CrossRef167
Delicia Munfus-McCray, Shuko Harada, Christina Adams, Frederic Askin, Douglas Clark, Edward Gabrielson, Qing Kay Li. (2011) EGFR and KRAS mutations in metastatic lung adenocarcinomas. Human Pathology 42:10, 1447-1453
CrossRef168
Antonio Passaro, Enrico Cortesi, Filippo de Marinis. (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy 11:10, 1587-1597
CrossRef169
Rabab M. Gaafar, Veerle F. Surmont, Giorgio V. Scagliotti, Rob J. Van Klaveren, Demetris Papamichael, John J. Welch, Baktiar Hasan, Valter Torri, Jan P. van Meerbeeck. (2011) A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). European Journal of Cancer 47:15, 2331-2340
CrossRef170
David J. Sugarbaker, Marcelo C. DaSilva. (2011) Diagnostic Workup of Lung Cancer. Surgical Oncology Clinics of North America 20:4, 667-679
CrossRef171
Manuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, Sumitra Thongprasert, Shun Lu, Gee-Chen Chang, Joseph Siu-Kie Au, Teh-Ying Chou, Jong-Seok Lee, Yuan-Kai Shi, Ahmad Radzi, Jin-Hyoung Kang, Sang-We Kim, Soo-Yong Tan, James Chih-Hsin Yang. (2011) Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:10, 1663-1669
CrossRef172
Goki Shindo, Takayoshi Endo, Masamitsu Onda, Yoju Miyamoto, Toru Kaneko, Shigenori Goto. (2011) Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers. Cancer Immunology, Immunotherapy 60:10, 1397-1403
CrossRef173
E. Bria, M. Milella, F. Cuppone, S. Novello, A. Ceribelli, V. Vaccaro, I. Sperduti, A. Gelibter, G. V. Scagliotti, F. Cognetti, D. Giannarelli. (2011) Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Annals of Oncology 22:10, 2277-2285
CrossRef174
F. Wang, L.D. Wang, B. Li, Z.X. Sheng. (2011) Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials. Clinical Oncology
CrossRef175
Henry Marshall, Steven Leong, Rayleen Bowman, Ian Yang, Kwun Fong. (2011) The Science Behind The 7th Edition TNM Staging System for Lung Cancer. Respirologyno-no
CrossRef176
A. Vilmar, J. Garcia-Foncillas, M. Huarriz, E. Santoni-Rugiu, J.B. Sorensen. (2011) RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer
CrossRef177
Athanasios G. Pallis, Vassilis Georgoulias. (2011) Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. Lung Cancer
CrossRef178
Thomas I. Peng Soh, Wei Peng Yong, Federico Innocenti. (2011) Review: Recent progress and clinical importance on pharmacogenetics in cancer therapy. Clinical Chemistry and Laboratory Medicine---
CrossRef179
Robert Pirker. (2011) Chemotherapy: Advanced NSCLC—should we use doublets in elderly patients?. Nature Reviews Clinical Oncology 8:12, 694-696
CrossRef180
Claudia Rossig, Heribert Juergens, Wolfgang E. Berdel. (2011) New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. Pediatric Hematology-Oncology 28:7, 539-555
CrossRef181
T. Brodowicz, T. Ciuleanu, J. Crawford, M. Filipits, J. R. Fischer, V. Georgoulias, C. Gridelli, F. R. Hirsch, J. Jassem, P. Kosmidis, M. Krzakowski, C. Manegold, J. L. Pujol, R. Stahel, N. Thatcher, J. Vansteenkiste, C. Minichsdorfer, S. Zochbauer-Muller, R. Pirker, C. C. Zielinski, . (2011) Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology
CrossRef182
Kit Man Wong, Thomas J. Hudson, John D. McPherson. (2011) Unraveling the Genetics of Cancer: Genome Sequencing and Beyond. Annual Review of Genomics and Human Genetics 12:1, 407-430
CrossRef183
Li Guo, Shu-Ping Bai, Ling Zhao, Xiao-Hong Wang. (2011) Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Medical Oncology
CrossRef184
Hidenori Tanaka, Tatsuo Kimura, Shinzoh Kudoh, Shigeki Mitsuoka, Tetsuya Watanabe, Tomohiro Suzumura, Keisei Tachibana, Masayuki Noguchi, Seiji Yano, Kazuto Hirata. (2011) Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. International Journal of Cancer 129:6, 1410-1416
CrossRef185
N. Ilic, T. Utermark, H. R. Widlund, T. M. Roberts. (2011) PNAS Plus: PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proceedings of the National Academy of Sciences 108:37, E699-E708
CrossRef186
Y Takada, L Gresh, A Bozec, E Ikeda, K Kamiya, M Watanabe, K Kobayashi, K Asano, Y Toyama, E F Wagner, K Matsuo. (2011) Interstitial lung disease induced by gefitinib and Toll-like receptor ligands is mediated by Fra-1. Oncogene 30:36, 3821-3832
CrossRef187
M. Pérol. (2011) Traitement d’induction et de maintenance des CBNPC au stade métastatique. Revue des Maladies Respiratoires Actualités 3:4, 365-371
CrossRef188
E. F. Smit. (2011) Medicatie bij longcarcinoom. Huisarts en wetenschap 54:9, 502-505
CrossRef189
Rodrigo Dienstmann, Enriqueta Felip. (2011) Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opinion on Biological Therapy 11:9, 1223-1231
CrossRef190
K.G. Tournoy, M. Carprieaux, E. Deschepper, J.P. van Meerbeeck, M. Praet. (2011) Are EUS–FNA and EBUS–TBNA specimens reliable for subtyping non-small cell lung cancer?. Lung Cancer
CrossRef191
Qiang Nie, Xue-ning Yang, She-juan An, Xu-chao Zhang, Jin-ji Yang, Wen-zhao Zhong, Ri-qiang Liao, Zhi-hong Chen, Jian Su, Zhi Xie, Yi-long Wu. (2011) CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism. European Journal of Cancer 47:13, 1962-1970
CrossRef192
C. Leduc, B. Mennecier. (2011) Quelle est la meilleure séquence thérapeutique chez les patients ayant un CBNPC avec mutation activatrice de l’EGFR ?. Revue des Maladies Respiratoires Actualités 3:4, 376-379
CrossRef193
Cesare Gridelli, Antonio Rossi, Paolo Maione. (2011) 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment — First-line therapy. European Journal of Cancer 47, S248-S257
CrossRef194
Rohit Lal, Deborah Enting, Hartmut Kristeleit. (2011) Systemic treatment of non-small-cell lung cancer. European Journal of Cancer 47, S375-S377
CrossRef195
Amandine Hurbin, Marie Wislez, Benoît Busser, Martine Antoine, Corine Tenaud, Nathalie Rabbe, Sandrine Dufort, Florence de Fraipont, Denis Moro-Sibilot, Jacques Cadranel, Jean-Luc Coll, Elisabeth Brambilla. (2011) Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. The Journal of Pathology 225:1, 83-95
CrossRef196
Yaping Xu, Yiping Zhang, Shenglin Ma. (2011) EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer 73:3, 249-255
CrossRef197
Filip Janku, Ignacio Garrido-Laguna, Lubos B. Petruzelka, David J. Stewart, Razelle Kurzrock. (2011) Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:9, 1601-1612
CrossRef198
Ana Custodio, Javier de Castro. (2011) Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology
CrossRef199
Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dong-Wan Kim, Soyeon Kim, Yoon-Kyung Jeon, Doo Hyun Chung, Woo-Ho Kim, Young Tae Kim, Seok-Chul Yang, Young Whan Kim, Dae Seog Heo, Yung-Jue Bang. (2011) Anaplastic Lymphoma Kinase Translocation. Journal of Thoracic Oncology 6:9, 1474-1480
CrossRef200
Hidetaka Uramoto, Hidehiko Shimokawa, Takeshi Hanagiri, Michihiko Kuwano, Mayumi Ono. (2011) Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer 73:3, 361-365
CrossRef201
D. Küster, S. Krüger. (2011) Pathologie und molekulare Pathologie von Lungentumoren. Der Pneumologe 8:5, 333-337
CrossRef202
Thomas E. Stinchcombe, Amy H. Peterman, Carrie B. Lee, Dominic T. Moore, Jennifer L. Beaumont, Daniel S. Bradford, Kamal Bakri, Mark Taylor, Jeffrey M. Crane, Garry Schwartz, Thomas A. Hensing, Edwin McElroy, Harvey B. Niell, Harry D. Harper, Sridhar Pal, Mark A. Socinski. (2011) A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:9, 1569-1577
CrossRef203
R. Veillon, J. Mazières. (2011) Résultats des stratégies ciblées des cancers bronchiques non à petites cellules en 2011. Revue des Maladies Respiratoires Actualités 3:4, 423-427
CrossRef204
Corey J. Langer. (2011) Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?. Clinical Lung Cancer 12:5, 272-279
CrossRef205
Paola Claudia Sacco, Paolo Maione, Antonio Rossi, Maria Anna Bareschino, Clorinda Schettino, Cesare Guida, Massimo Elmo, Rita Ambrosio, Valentina Barbato, Rosario Zeppa, Giovanni Palazzolo, Cesare Gridelli. (2011) Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Targeted Oncology 6:3, 171-180
CrossRef206
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef207
Feng Pan, Jing Tian, Xuchao Zhang, Ying Zhang, Yueyin Pan. (2011) Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology 137:9, 1397-1408
CrossRef208
Thomas A. D'Amico. (2011) Invited Commentary. The Annals of Thoracic Surgery 92:3, 1050
CrossRef209
Keith M Kerr. (2011) Personalized medicine for lung cancer: new challenges for pathology. Histopathologyno-no
CrossRef210
Filippo de Marinis, Serena Ricciardi. (2011) Second-line treatment options in advanced non-small cell lung cancer. European Journal of Cancer 47, S258-S271
CrossRef211
Hee Joung Kim, Kye Young Lee, Young-Chul Kim, Kyu-Sik Kim, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong-Cheol Shin, Gwan Ho Lee, Jae Chol Lee, Jeong Eun Lee, Sun Young Kim. (2011) Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer
CrossRef212
Patrick Royston, Mahesh K. B. Parmar. (2011) The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine 30:19, 2409-2421
CrossRef213
Lorenza Landi, Federico Cappuzzo. (2011) Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. Nature Reviews Clinical Oncology 8:10, 571-573
CrossRef214
H Schultz, S Marwitz, B Baron-Lühr, G Zissel, C Kugler, K F Rabe, P Zabel, E Vollmer, J Gerdes, T Goldmann. (2011) Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung. British Journal of Cancer 105:5, 673-681
CrossRef215
Tony S. K. Mok. (2011) Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology 8:11, 661-668
CrossRef216
Tomonori Hirashima, Hidekazu Suzuki, Masashi Kobayashi, Youko Kondoh, Yoshie Tokuoka, Yuka Matsuura, Motohiro Tamiya, Naoko Morishita, Shinji Sasada, Norio Okamoto, Kohei Akazawa, Ichiro Kawase. (2011) Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. Medical Oncology
CrossRef217
Kazuhiro Asami, Masaaki Kawahara, Shinji Atagi, Tomoya Kawaguchi, Kyoichi Okishio. (2011) Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 73:2, 211-216
CrossRef218
W.E.E. Eberhardt, T.C. Gauler, S. Welter, T. Krbek, M. Stuschke, C. Pöttgen. (2011) Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. Der Onkologe 17:8, 691-701
CrossRef219
A. M. Horgan, P. A. Bradbury, E. Amir, R. Ng, J. Y. Douillard, E. S. Kim, F. A. Shepherd, N. B. Leighl. (2011) An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Annals of Oncology 22:8, 1805-1811
CrossRef220
Thomas E. Stinchcombe, Jeffery Bogart, Nirmal K. Veeramachaneni, Robert Kratzke, Ramaswamy Govindan. (2011) Annual Review of Advances in Non-small Cell Lung Cancer Research. Journal of Thoracic Oncology 6:8, 1443-1450
CrossRef221
M. Kobayashi, K. Matsui, N. Katakami, K. Takeda, A. Moriyama, Y. Iwamoto, M. Takada, H. Yoshioka, N. Sueoka-Aragane, K. Nakagawa, . (2011) Phase II Study of Gefitinib as a First-line Therapy in Elderly Patients with Pulmonary Adenocarcinoma: West Japan Thoracic Oncology Group Study 0402. Japanese Journal of Clinical Oncology 41:8, 948-952
CrossRef222
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 12:8, 735-742
CrossRef223
F. Griesinger. (2011) Systemische Therapie des nichtkleinzelligen Lungenkarzinoms. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 25:4, 224-230
CrossRef224
Katsuhiko Naoki, Kenzo Soejima, Hiroaki Okamoto, Junko Hamamoto, Naoya Hida, Ichiro Nakachi, Hiroyuki Yasuda, Sohei Nakayama, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Koshiro Watanabe. (2011) The PCR-invader method (structure-specific 5′ nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. International Journal of Clinical Oncology 16:4, 335-344
CrossRef225
Sapna P. Patel, Kevin B. Kim, Nicholas E. Papadopoulos, Wen-Jen Hwu, Patrick Hwu, Victor G. Prieto, Menashe Bar-Eli, Maya Zigler, Andrey Dobroff, Yulia Bronstein, Roland L. Bassett, Anna G. Vardeleon, Agop Y. Bedikian. (2011) A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Research 21:4, 357-363
CrossRef226
Shirish M. Gadgeel. (2011) The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients. Current Oncology Reports 13:4, 272-279
CrossRef227
Howard West. (2011) The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer. Current Oncology Reports 13:4, 280-289
CrossRef228
L.C. Heukamp, J. Wolf, R. Büttner. (2011) Pathophysiologie und Molekulardiagnostik beim nichtkleinzelligen Lungenkarzinom. Der Onkologe 17:8, 670-678
CrossRef229
Kenichi Suda, Kenji Tomizawa, Yasushi Yatabe, Tetsuya Mitsudomi. (2011) Lung cancers unrelated to smoking: characterized by single oncogene addiction?. International Journal of Clinical Oncology 16:4, 294-305
CrossRef230
S. Matsuura, N. Inui, Y. Ozawa, Y. Nakamura, M. Toyoshima, K. Yasuda, T. Yamada, T. Shirai, H. Suganuma, K. Yokomura, T. Suda, K. Chida. (2011) Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations. Japanese Journal of Clinical Oncology 41:8, 959-963
CrossRef231
Hironori Satoh, Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Yasuo Saijo, Hirohisa Yoshizawa, Koichi Hagiwara, Toshihiro Nukiwa. (2011) Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology 6:8, 1413-1417
CrossRef232
Yoshihiko Maehara. (2011) Primary lung cancer in never smokers. International Journal of Clinical Oncology 16:4, 285-286
CrossRef233
Tetsuya Mitsudomi. (2011) Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. The Lancet Oncology 12:8, 710-711
CrossRef234
Kenneth J O'Byrne, Ulrich Gatzemeier, Igor Bondarenko, Carlos Barrios, Corinna Eschbach, Uwe M Martens, Yevhen Hotko, Cornelius Kortsik, Luis Paz-Ares, Jose R Pereira, Joachim von Pawel, Rodryg Ramlau, Jae-Kyung Roh, Chih-Teng Yu, Christopher Stroh, Ilhan Celik, Armin Schueler, Robert Pirker. (2011) Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. The Lancet Oncology 12:8, 795-805
CrossRef235
Anastasios Dimou, Seema Agarwal, Valsamo Anagnostou, Hollis Viray, Stephen Christensen, Bonnie Gould Rothberg, Vassiliki Zolota, Konstantinos Syrigos, David L. Rimm. (2011) Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer. The American Journal of Pathology 179:2, 580-589
CrossRef236
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl. (2011) A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1379-1391
CrossRef237
F. Tanaka, H. Wada, Y. Fukui, M. Fukushima. (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Annals of Oncology 22:8, 1791-1797
CrossRef238
Chih-Chia Chang, Kwan-Hwa Chi, Shang-Jyh Kao, Pei-Sung Hsu, Yuk-Wah Tsang, Heng-Jui Chang, Yu-Wung Yeh, Yei-San Hsieh, Jiunn-Song Jiang. (2011) Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience. Lung Cancer 73:2, 189-194
CrossRef239
Andrew J Weickhardt, D Ross Camidge. (2011) The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clinical Investigation 1:8, 1119-1126
CrossRef240
H. K. Chew, G. Somlo, P. C. Mack, B. Gitlitz, R. Gandour-Edwards, S. Christensen, H. Linden, L. J. Solis, X. Yang, A. M. Davies. (2011) Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Annals of Oncology
CrossRef241
E.- H. Tan, C. Goh, W. T. Lim, K. C. Soo, M. L. Khoo, T. Tan, D. S. W. Tan, M. K. Ang, Q. S. Ng, P. H. Tan, A. Lim, J. Hwang, Y. H. F. Teng, T. H. Lim, S. H. Tan, N. Baskaran, K. M. Hui. (2011) Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of Oncology
CrossRef242
Alice De Sanctis, Laurent Taillade, Stephane Vignot, Silvia Novello, Rosa Conforti, Jean Philippe Spano, Giorgio Vittorio Scagliotti, David Khayat. (2011) Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer 117:14, 3069-3080
CrossRef243
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Shaw, Alice T., Forcione, David G., Digumarthy, Subba R., Iafrate, A. John, . (2011) Case 21-2011. New England Journal of Medicine 365:2, 158-167
Full Text244
B. Schultheis, G. Kummer, M. Zeth, E. Brendel, C. Xia, M. Kornacker, D. Strumberg. (2011) Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology
CrossRef245
J. Chmielecki, J. Foo, G. R. Oxnard, K. Hutchinson, K. Ohashi, R. Somwar, L. Wang, K. R. Amato, M. Arcila, M. L. Sos, N. D. Socci, A. Viale, E. de Stanchina, M. S. Ginsberg, R. K. Thomas, M. G. Kris, A. Inoue, M. Ladanyi, V. A. Miller, F. Michor, W. Pao. (2011) Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine 3:90, 90ra59-90ra59
CrossRef246
Filippo de Marinis, Antonio Rossi, Massimo Di Maio, Serena Ricciardi, Cesare Gridelli. (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1, 1-10
CrossRef247
Marie Brevet, Melissa L. Johnson, Christopher G. Azzoli, Marc Ladanyi. (2011) Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73:1, 96-102
CrossRef248
Dora Dias-Santagata, Quynh Lam, Kristin Bergethon, Gabrielle M Baker, A John Iafrate, Dinesh Rakheja, Mai P Hoang. (2011) A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Modern Pathology 24:7, 974-982
CrossRef249
Nagahiro Saijo. (2011) Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treatment Reviews
CrossRef250
Monica Arnedos, Fabrice Andre. (2011) Tumor genotyping for breast cancer: at the front door. Personalized Medicine 8:4, 383-385
CrossRef251
William D. Travis. (2011) Classification of Lung Cancer. Seminars in Roentgenology 46:3, 178-186
CrossRef252
E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel, . (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology 22:7, 1507-1519
CrossRef253
Jaclyn Yoong, Michael Michael, Trevor Leong. (2011) Targeted Therapies for Gastric Cancer. Drugs 71:11, 1367-1384
CrossRef254
A. Cortot, E. Dansin, A. Scherpereel. (2011) Oncologie thoracique. Revue des Maladies Respiratoires Actualités 3:6, 158-165
CrossRef255
Hans-Georg Eichler, Eric Abadie, Alasdair Breckenridge, Bruno Flamion, Lars L. Gustafsson, Hubert Leufkens, Malcolm Rowland, Christian K. Schneider, Brigitte Bloechl-Daum. (2011) Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response. Nature Reviews Drug Discovery 10:7, 495-506
CrossRef256
Ming Liu, Gening Jiang, Wenxin He, Peng Zhang, Nan Song. (2011) Surgical Resection of Locally Advanced Pulmonary Adenocarcinoma After Gefitinib Therapy. The Annals of Thoracic Surgery 92:1, e11-e12
CrossRef257
A G Pallis, D A Fennell, E Szutowicz, N B Leighl, L Greillier, R Dziadziuszko. (2011) Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer 105:1, 1-8
CrossRef258
Stefan Michiels, Richard F. Potthoff, Stephen L. George. (2011) Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. Statistics in Medicine 30:13, 1502-1518
CrossRef259
C. Tibaldi, E. Giovannetti, M. Tiseo, L. G. Leon, A. D'Incecco, N. Loosekoot, M. Bartolotti, R. Honeywell, F. Cappuzzo, A. Ardizzoni, G. J. Peters. (2011) Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Annals of Oncology
CrossRef260
Alfredo Tartarone, Rose Lerose, Giuseppina Gallucci, Raffaele Ardito, Michele Aieta. (2011) Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. Medical Oncology
CrossRef261
G. T. Bergkvist, D. A. Yool. (2011) Epidermal growth factor receptor as a therapeutic target in veterinary oncology. Veterinary and Comparative Oncology 9:2, 81-94
CrossRef262
Kanwal Pratap Singh Raghav, George R Blumenschein. (2011) Motesanib and advanced NSCLC: experiences and expectations. Expert Opinion on Investigational Drugs 20:6, 859-869
CrossRef263
Hao-Wei Teng, Hsei-Wei Wang, Wei-Ming Chen, Ta-Chung Chao, Yao-Yu Hsieh, Chi-Hsiu Hsih, Cheng-Hwai Tzeng, Paul Chih-Hsueh Chen, Chueh-Chuan Yen. (2011) Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. Journal of Surgical Oncology 103:8, 773-781
CrossRef264
Gee-Chen CHANG, Myung-Ju AHN, Elaine WRIGHT, Heung Tae KIM, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Steven SHERMAN, Stefan WALZER. (2011) Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia-Pacific Journal of Clinical Oncology 7, 34-40
CrossRef265
György Marko-Varga, Thomas E. Fehniger, Melinda Rezeli, Balázs Döme, Thomas Laurell, Ákos Végvári. (2011) Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. Journal of Proteomics 74:7, 982-992
CrossRef266
M. Früh. (2011) The search for improved systemic therapy of non-small cell lung cancer—What are today's options?. Lung Cancer 72:3, 265-270
CrossRef267
Chun-Ming Tsai, Joseph Siu-kie Au, Gee-Chen Chang, Ashley Chi-kin Cheng, Caicun Zhou, Yi-long Wu. (2011) Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology 6:6, 1092-1097
CrossRef268
Jessica S. Donington, Yolonda L. Colson. (2011) Sex and Gender Differences in Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 23:2, 137-145
CrossRef269
Valery Elie, Tiphaine de Beaumais, May Fakhoury, Evelyne Jacqz-Aigrain. (2011) Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. Pharmacogenomics 12:6, 827-843
CrossRef270
Kuo-Hsuan Hsu, Kun-Chieh Chen, Tsung-Ying Yang, Yi-Chen Yeh, Teh-Ying Chou, Hsuan-Yu Chen, Chi-Ren Tsai, Chih-Yi Chen, Chung-Ping Hsu, Jiun-Yi Hsia, Cheng-Yen Chuang, Ying-Huang Tsai, Kuan-Yu Chen, Ming-Shyan Huang, Wu-Chou Su, Yuh-Min Chen, Chao A. Hsiung, Gee-Chen Chang, Chien-Jen Chen, Pan-Chyr Yang. (2011) Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. Journal of Thoracic Oncology 6:6, 1066-1072
CrossRef271
B. Besse, G. Zalcman. (2011) Quelle séquence de traitement chez les patients EGFR mutés ?. Revue de Pneumologie Clinique 67, S24-S29
CrossRef272
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy, Satish K. Tickoo, Samson W. Fine, Anuradha Gopalan, Ying-bei Chen, Arjun Balar, Jamie Riches, Bernard Bochner, Guido Dalbagni, Dean F. Bajorin, Victor E. Reuter, Matthew I. Milowsky, David B. Solit. (2011) Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. The Journal of Pathology 224:2, 270-279
CrossRef273
Mark Murphy, Britta Stordal. (2011) Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: A systematic review. Drug Resistance Updates 14:3, 177-190
CrossRef274
Yuh-Min Chen, Wen-Chien Fan, Chun-Ming Tsai, Shih-Hao Liu, Jen-Fu Shih, Teh-Ying Chou, Chieh-Hung Wu, Kun-Ta Chou, Yu-Chin Lee, Reury-Perng Perng, Jacqueline Whang-Peng. (2011) A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy. Journal of Thoracic Oncology 6:6, 1110-1116
CrossRef275
Matthias Scheffler, Paola Di Gion, Oxana Doroshyenko, Jürgen Wolf, Uwe Fuhr. (2011) Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics 50:6, 371-403
CrossRef276
Alain Makinson, Jean-Charles Tenon, Sabrina Eymard-Duvernay, Jean-Louis Pujol, Clotilde Allavena, Lise Cuzin, Isabelle Poizot-Martin, Xavier de la Tribonnière, André Cabié, Pascal Pugliese, Jacques Reynes, Vincent Le Moing. (2011) Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:6, 1022-1029
CrossRef277
Yuh-Min Chen, Jacqueline Whang-Peng, Chien-Ming Chen. (2011) First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review. Journal of Experimental & Clinical Medicine 3:3, 116-120
CrossRef278
D. Moro-Sibilot. (2011) Quel choix de traitement en première ligne ?. Revue de Pneumologie Clinique 67, S20-S23
CrossRef279
Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, Vincent A. Miller. (2011) Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. Journal of Thoracic Oncology 6:6, 1128-1131
CrossRef280
D. Planchard, E. Giroux Leprieur. (2011) Biomarqueurs et thérapies ciblées dans le cancer bronchique non à petites cellules : traitement d’aujourd’hui et de demain. Revue de Pneumologie Clinique 67, S36-S40
CrossRef281
C.P. Belani, G. Goss, G. Blumenschein. (2011) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews
CrossRef282
Zhi-jie Wang, Tong-tong An, Tony Mok, Lu Yang, Hua Bai, Jun Zhao, Jian-chun Duan, Mei-na Wu, Yu-yan Wang, Ping-ping Li, Hong Sun, Ping Yang, Jie Wang. (2011) Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chinese Journal of Cancer Research 23:2, 112-117
CrossRef283
V KimCurran, C Zhou, G Schmid-Bindert, Ren Shengxiang, S Zhou, L Zhang, J Zhang. (2011) Lack of correlation between ERCC1 (C8092A) Single Nucleotide Polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced Non-Small Cell Lung Cancer. Advances in Medical Sciences 56:1, 30-38
CrossRef284
Tony SK MOK. (2011) Bevacizumab in the treatment of non-small cell lung cancer: focus on East Asia. Asia-Pacific Journal of Clinical Oncology 7, 1-3
CrossRef285
Michèle Beau-Faller, Armelle Degeorges, Estelle Rolland, Mounia Mounawar, Martine Antoine, Virginie Poulot, Audrey Mauguen, Véronique Barbu, Florence Coulet, Jean-Luc Prétet, Ivan Bièche, Hélène Blons, Jean-Christophe Boyer, Marie-Pierre Buisine, Florence de Fraipont, Sarab Lizard, Sylviane Olschwang, Patrick Saulnier, Delphine Prunier-Mirebeau, Nicolas Richard, Claire Danel, Elisabeth Brambilla, Christos Chouaid, Gérard Zalcman, Pierre Hainaut, Stefan Michiels, Jacques Cadranel. (2011) Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples. Journal of Thoracic Oncology 6:6, 1006-1015
CrossRef286
Mariacarmela Santarpia, Giuseppe Altavilla, Maria F Salazar, Ignacio Magri, Giuseppe Pettineo, Sara Benecchi, Rafael Rosell. (2011) Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine 5:3, 413-424
CrossRef287
F. Barlesi. (2011) Prise en charges des patients présentant une résistance aux TKI de l’EGFR. Revue de Pneumologie Clinique 67, S30-S35
CrossRef288
F. Lokiec, J.-Y. Douillard. (2011) Inhibiteurs de tyrosine kinase (TKI) de l’EGFR : similitudes et différences. Revue de Pneumologie Clinique 67, S15-S19
CrossRef289
J. Cadranel, E. Giroux Leprieur. (2011) Prélèvement et recherche de la mutation EGFR : quoi prélever, quand et comment tester ?. Revue de Pneumologie Clinique 67, S9-S14
CrossRef290
Makoto Sonobe, Masashi Kobayashi, Masashi Ishikawa, Ryutaro Kikuchi, Ei Nakayama, Tsuyoshi Takahashi, Toshi Menju, Kazumasa Takenaka, Ryo Miyahara, Cheng-Long Huang, Kenichi Okubo, Toru Bando, Hiroshi Date. (2011) Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas. Annals of Surgical Oncology
CrossRef291
R. Katayama, T. M. Khan, C. Benes, E. Lifshits, H. Ebi, V. M. Rivera, W. C. Shakespeare, A. J. Iafrate, J. A. Engelman, A. T. Shaw. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proceedings of the National Academy of Sciences 108:18, 7535-7540
CrossRef292
, Helmut Popper, Fritz Wrba, Ulrike Gruber-Mösenbacher, Wolfgang Hulla, Robert Pirker, Wolfgang Hilbe, Michael Studnicka, Andrea Mohn-Staudner, Ferdinand Ploner. (2011) Histologie-basierter Algorithmus der molekularen Diagnostik des epidermalen Wachstumsfaktor-Rezeptorgens (Epidermal Growth Factor Receptor, EGFR) beim nicht-kleinzelligen Lungenkarzinom (non-small cell lung cancer, NSCLC)*. Wiener klinische Wochenschrift 123:9-10, 316-321
CrossRef293
Jingwei Jiang, Lizhen Huang, Xiaohua Liang, Xinli Zhou, Ruofan Huang, Zhaohui Chu, Qiong Zhan. (2011) Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Acta Oncologica 50:4, 582-588
CrossRef294
Cesar Moran. (2011) Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment. The American Journal of Pathology 178:5, 1940-1948
CrossRef295
Jenn-Yu Wu, Shang-Gin Wu, Chih-Hsin Yang, Yih-Leong Chang, Yeun-Chung Chang, Ya-Chieh Hsu, Jin-Yuan Shih, Pan-Chyr Yang. (2011) Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 72:2, 205-212
CrossRef296
Tony S. K. Mok, Kwok Chi Lam. (2011) The Diverse Diversity. Journal of Thoracic Oncology 6:5, 842-843
CrossRef297
Sacha Rothschild, Stephan E. Bucher, Jacques Bernier, Daniel M. Aebersold, Aberrahim Zouhair, Gerhard Ries, Norbert Lombrieser, Thomas Lippuner, Urs M. Lütolf, Christoph Glanzmann, I. Frank Ciernik. (2011) Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non–Small Cell Lung Cancer: A Phase I Trial. International Journal of Radiation Oncology*Biology*Physics 80:1, 126-132
CrossRef298
Jennifer Levin Carter, Sheryl Elkin, Joan Barton. (2011) Company Profile: N-of-One: realizing personalized medicine. Personalized Medicine 8:3, 311-315
CrossRef299
Mark A. Kay. (2011) State-of-the-art gene-based therapies: the road ahead. Nature Reviews Genetics 12:5, 316-328
CrossRef300
Adi F. Gazdar. (2011) Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer. Medicine 90:3, 168-170
CrossRef301
Giulio Metro, Lucio Crinò. (2011) The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy 11:5, 673-682
CrossRef302
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef303
Herbert H. Loong, Jia Wei, Tony S. Mok. (2011) Ethnic variation in response to EGFR inhibitors. Drug Discovery Today: Therapeutic Strategies
CrossRef304
Denise A. Chan, Amato J. Giaccia. (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nature Reviews Drug Discovery 10:5, 351-364
CrossRef305
Youngil Koh, Dong-Wan Kim, Tae Min Kim, Se-Hoon Lee, Yoon Kyung Jeon, Doo Hyun Chung, Young-Whan Kim, Dae Seog Heo, Woo-Ho Kim, Yung-Jue Bang. (2011) Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma. Journal of Thoracic Oncology 6:5, 905-912
CrossRef306
Akihiko Yoshizawa, Noriko Motoi, Gregory J Riely, Cami S Sima, William L Gerald, Mark G Kris, Bernard J Park, Valerie W Rusch, William D Travis. (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology 24:5, 653-664
CrossRef307
Åslaug Helland, Hege Marian Skaug, Lilach Kleinberg, Marius Lund Iversen, Ane Kongsgaard Rud, Thomas Fleischer, Camilla Sagerup, Steinar Solberg, Lars Jørgensen, Sarah Ariansen, Odd Terje Brustugun. (2011) EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery. Journal of Thoracic Oncology 6:5, 947-950
CrossRef308
David Berz, Harold Wanebo. (2011) Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology 103:6, 574-586
CrossRef309
Takehito Shukuya, Toshiaki Takahashi, Rieko Kaira, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Kazuhisa Takahashi, Nobuyuki Yamamoto. (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Science 102:5, 1032-1037
CrossRef310
Niels Reinmuth, Michael Thomas. (2011) An approach to personalized medicine: the BATTLE trial. Clinical Investigation 1:5, 699-705
CrossRef311
Jenn-Yu Wu, Jin-Yuan Shih, Kuan-Yu Chen, Chih-Hsin Yang, Chong-Jen Yu, Pan-Chyr Yang. (2011) Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations. Medicine 90:3, 159-167
CrossRef312
Isamu Okamoto, Toshiaki Takahashi, Hiroaki Okamoto, Kazuhiko Nakagawa, Koshiro Watanabe, Kiyoshi Nakamatsu, Yasumasa Nishimura, Masahiro Fukuoka, Nobuyuki Yamamoto. (2011) Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 72:2, 199-204
CrossRef313
Harubumi Kato, Toshihide Nishimura, Norihiko Ikeda, Tesshi Yamada, Tadashi Kondo, Nagahiro Saijo, Kazuto Nishio, Junichiro Fujimoto, Masaharu Nomura, Yoshiya Oda, Bertil Lindmark, Jiro Maniwa, Hitoshi Hibino, Michiaki Unno, Toshinori Ito, Yoshiki Sawa, Hiromasa Tojo, Shin Egawa, Goutham Edula, Mary Lopez, Murray Wigmore, Naohiko Inase, Yasuyuki Yoshizawa, Fumio Nomura, György Marko-Varga. (2011) Developments for a growing Japanese patient population: Facilitating new technologies for future health care. Journal of Proteomics 74:6, 759-764
CrossRef314
Gilda da Cunha Santos, Mauro Ajaj Saieg, William Geddie, Natasha Leighl. (2011) EGFR gene status in cytological samples of nonsmall cell lung carcinoma. Cancer Cytopathology 119:2, 80-91
CrossRef315
Nazneen Fatima, Cynthia Cohen, Diane Lawson, Momin T. Siddiqui. (2011) TTF-1 and Napsin A double stain. Cancer Cytopathology 119:2, 127-133
CrossRef316
Xing-Yang Xue, Ming Zhou, Wen-Fan Fu, You-Guang Pan, Jian Zhao. (2011) Colonic metastasis from primary lung adenocarcinoma: case report and review of the literature. Medical Oncology
CrossRef317
T Harada, A Lopez-Chavez, L Xi, M Raffeld, Y Wang, G Giaccone. (2011) Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene 30:15, 1744-1752
CrossRef318
Heidi Mc Kean, Philip J. Stella, Shauna L. Hillman, Kendrith M. Rowland, Michael W. Cannon, Robert J. Behrens, Gerald G. Gross, Mark D. Sborov, Eliot L. Friedman, Aminah Jatoi. (2011) Exploring Therapeutic Decisions in Elderly Patients with Non-Small Cell Lung Cancer: Results and Conclusions from North Central Cancer Treatment Group Study N0222. Cancer Investigation 29:4, 266-271
CrossRef319
Alicia Okines, David Cunningham, Ian Chau. (2011) Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology 8:8, 492-503
CrossRef320
Young Joo Lee, Joo-Hang Kim, Se Kyu Kim, Sang-Jun Ha, Tony S. Mok, Tetsuya Mitsudomi, Byoung Chul Cho. (2011) Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer 72:1, 9-15
CrossRef321
Paul Workman, Paul A. Clarke. (2011) Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR. Cancer Cell 19:4, 437-440
CrossRef322
Y. Koh, B. Jang, Y. K. Jeon, T. M. Kim, S.-H. Lee, D.-W. Kim, D. H. Chung, Y. T. Kim, Y. W. Kim, D. S. Heo. (2011) EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. Japanese Journal of Clinical Oncology 41:4, 548-554
CrossRef323
Daniel A. Haber, Nathanael S. Gray, Jose Baselga. (2011) The Evolving War on Cancer. Cell 145:1, 19-24
CrossRef324
Gwyn Bebb, Colum Smith, Stewart Rorke, William Boland, Leonardo Nicacio, Ryan Sukhoo, Anthony Brade. (2011) Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemotherapy and Pharmacology 67:4, 837-845
CrossRef325
Ravi Salgia, Thomas Hensing, Nicholas Campbell, April K. Salama, Michael Maitland, Philip Hoffman, Victoria Villaflor, Everett E. Vokes. (2011) Personalized Treatment of Lung Cancer. Seminars in Oncology 38:2, 274-283
CrossRef326
C. Gridelli, F. De Marinis, M. Di Maio, D. Cortinovis, F. Cappuzzo, T. Mok. (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues. Lung Cancer 72:1, 3-8
CrossRef327
Nupura S Bhise, Ron B Shmueli, Joel C Sunshine, Stephany Y Tzeng, Jordan J Green. (2011) Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opinion on Drug Delivery 8:4, 485-504
CrossRef328
Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Rita Chiari, Vincenzo Minotti, Renato Colella, Dario Giuffrida, Francesca Romana Tofanetti, Annamaria Siggillino, Antonella Flacco, Elisa Baldelli, Daniela Iacono, Maria Grazia Mameli, Antonio Cavaliere, Lucio Crinò. (2011) Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:4, 707-715
CrossRef329
D. Ross Camidge, Scott A. Kono, Xian Lu, Sonia Okuyama, Anna E. Barón, Ana B. Oton, Angela M. Davies, Marileila Varella-Garcia, Wilbur Franklin, Robert C. Doebele. (2011) Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed. Journal of Thoracic Oncology 6:4, 774-780
CrossRef330
A.-M. Ruppert, M. Wislez, V. Poulot, R. Lacave, M. Antoine, J. Cadranel. (2011) Un regard simple sur la biologie du cancer bronchique : EGFR. Revue des Maladies Respiratoires 28:4, 565-577
CrossRef331
Mizuki Nishino, David M. Jackman, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson, Annick D. Van den Abbeele. (2011) Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology 18:4, 424-436
CrossRef332
Thomas Stricker, Daniel V.T. Catenacci, Tanguy Y. Seiwert. (2011) Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology 38:2, 173-185
CrossRef333
E. Szutowicz, K. Konopa, J. Jassem. (2011) Targeted therapies in advanced non-small cell lung cancer: success or failure?. memo - Magazine of European Medical Oncology 4:1, 23-26
CrossRef334
Jong-Mu Sun, Young-Woong Won, Seung Tae Kim, Jung Hoon Kim, Yoon-La Choi, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2011) The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology 137:4, 687-694
CrossRef335
Madhuri V Warren, WY Iris Chan, John M Ridley. (2011) Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis. Biomarkers in Medicine 5:2, 227-248
CrossRef336
R. L. Schilsky. (2011) Accrual to Cancer Clinical Trials in the Era of Molecular Medicine. Science Translational Medicine 3:75, 75cm9-75cm9
CrossRef337
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman. (2011) Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine 3:75, 75ra26-75ra26
CrossRef338
Cataldo, Vince D., Gibbons, Don L., Pérez-Soler, Román, Quintás-Cardama, Alfonso, . (2011) Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine 364:10, 947-955
Full Text339
A.- M. C. Dingemans, A. J. de Langen, V. van den Boogaart, J. T. Marcus, W. H. Backes, H. T. G. M. Scholtens, H. van Tinteren, O. S. Hoekstra, J. Pruim, B. Brans, F. B. Thunnissen, E. F. Smit, H. J. M. Groen. (2011) First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology 22:3, 559-566
CrossRef340
Athanasios G. Pallis, Kostas Syrigos, Athanasios Kotsakis, Niki Karachaliou, Aris Polyzos, Vassilis Chandrinos, Ioannis Varthalitis, Charalambos Christophyllakis, Alexandros Ardavanis, Lambros Vamvakas, Nikolaos Vardakis, Zacharenia Saridaki, George Samonis, Stylianos Giassas, Vassilis Georgoulias, Sophia Agelaki. (2011) Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study. Clinical Lung Cancer 12:2, 100-105
CrossRef341
Dennis A. Wigle. (2011) Personalized Therapy for Non–Small Cell Lung Cancer: Hype or Clinical Reality?. Seminars in Thoracic and Cardiovascular Surgery 23:1, 30-35
CrossRef342
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef343
Rita Nizzoli, Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Maria Majori, Lilia Ferrari, Massimo De Filippo, Guido Rindi, Enrico Maria Silini, Annamaria Guazzi, Andrea Ardizzoni. (2011) Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:3, 489-493
CrossRef344
Yelena Y. Janjigian, Bernard J. Park, Maureen F. Zakowski, Marc Ladanyi, William Pao, Sandra P. DʼAngelo, Mark G. Kris, Ronglai Shen, Junting Zheng, Christopher G. Azzoli. (2011) Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology 6:3, 569-575
CrossRef345
Julien Hadoux, Benjamin Besse, David Planchard. (2011) Cancers bronchiques des non-fumeurs : particularités épidémiologiques, thérapeutiques et moléculaires. La Presse Médicale
CrossRef346
Hua Cheng, She-Juan An, Xu-Chao Zhang, Song Dong, Yi-Fang Zhang, Zhi-Hong Chen, Hua-Jun Chen, Ai-Lin Guo, Qiu-xiong Lin, Yi-Long Wu. (2011) In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology 67:3, 637-646
CrossRef347
C. Gridelli, F. De Marinis, M. Di Maio, D. Cortinovis, F. Cappuzzo, T. Mok. (2011) Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 71:3, 249-257
CrossRef348
Christian Ensinger. (2011) Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. Expert Opinion on Medical Diagnostics 5:2, 91-94
CrossRef349
Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen, Yan-Xia Shi, Li Zhang. (2011) Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib. Medical Oncology 28:1, 331-335
CrossRef350
Frank C. Detterbeck. (2011) Maintaining Aim at a Moving Target. Journal of Thoracic Oncology 6:3, 417-422
CrossRef351
Marc Buyse, Stefan Michiels, Daniel J Sargent, Axel Grothey, Alastair Matheson, Aimery de Gramont. (2011) Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 11:2, 171-182
CrossRef352
Linda E. Coate, Natasha B. Leighl. (2011) How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology 12:1, 1-11
CrossRef353
Laureline Le Maignan, Delphine Mirebeau-Prunier, Laurent Vervueren, Thierry Jeanfaivre, Thierry Urban, José Hureaux. (2011) First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib. Journal of Thoracic Oncology 6:3, 639-640
CrossRef354
Jin Ho Paik, Gheeyoung Choe, Hyojin Kim, Ji-Young Choe, Hyun Ju Lee, Choon-Taek Lee, Jong Seok Lee, Sanghoon Jheon, Jin-Haeng Chung. (2011) Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:3, 466-472
CrossRef355
Deepa S Subramaniam, Jimmy Hwang. (2011) BIBW 2992 in non-small cell lung cancer. Expert Opinion on Investigational Drugs 20:3, 415-422
CrossRef356
Naohiro Nose, Hidetaka Uramoto, Teruo Iwata, Takeshi Hanagiri, Kosei Yasumoto. (2011) Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR–TKI for adenocarcinoma of the lung. Lung Cancer 71:3, 350-355
CrossRef357
Cesare Gridelli. (2011) First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?. Current Opinion in Oncology 23:2, 131-132
CrossRef358
Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri. (2011) Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians 61:2, 91-112
CrossRef359
Giannis Mountzios, Kostas N. Syrigos. (2011) A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. Drug Safety 34:3, 175-186
CrossRef360
F. Cappuzzo, D. R. Camidge, M. Varella-Garcia. (2011) Is FISH floating or still swimming in the lung cancer ocean?. Annals of Oncology 22:3, 493-499
CrossRef361
Chien-Hao Lie, Huang-Chih Chang, Tung-Ying Chao, Yu-Hsiu Chung, Jui-Long Wang, Chin-Chou Wang, Meng-Chih Lin. (2011) First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan. Clinical Lung Cancer 12:2, 116-124
CrossRef362
Peng Chen, Long Wang, Bing Liu, Hai-Zhong Zhang, Hong-Chen Liu, Zui Zou. (2011) EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. European Journal of Clinical Pharmacology 67:3, 235-243
CrossRef363
Cesare Gridelli, Paolo Maione, Antonio Rossi, Maria Anna Bareschino, Clorinda Schettino, Paola Claudia Sacco, Rosario Zeppa. (2011) Pemetrexed in advanced non-small cell lung cancer. Expert Opinion on Drug Safety 10:2, 311-317
CrossRef364
Michele L. Cote, Ramsi Haddad, David J. Edwards, Govindaraja Atikukke, Shirish Gadgeel, Ayman O. Soubani, Fulvio Lonardo, Gerold Bepler, Ann G. Schwartz, Stephen P. Ethier. (2011) Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:3, 627-630
CrossRef365
Sabina Antonela Antoniu. (2011) Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?. Expert Opinion on Therapeutic Targets 15:3, 351-353
CrossRef366
Gilda da Cunha Santos, Frances A. Shepherd, Ming Sound Tsao. (2011) EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease 6:1, 49-69
CrossRef367
Karen Reckamp, Barbara Gitlitz, Lin-Chi Chen, Ravi Patel, Ginger Milne, Mary Syto, Deborah Jezior, Sara Zaknoen. (2011) Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 117:4, 809-818
CrossRef368
Eric D. Green, Mark S. Guyer, Eric D. Green, Mark S. Guyer, Teri A. Manolio, Jane L. Peterson. (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470:7333, 204-213
CrossRef369
Sandra P. D’Angelo, Bernard Park, Christopher G. Azzoli, Mark G. Kris, Valerie Rusch, Marc Ladanyi, Maureen F. Zakowski. (2011) Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center. The Journal of Thoracic and Cardiovascular Surgery 141:2, 476-480
CrossRef370
William D. Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James Jett, Montserrat Sanchez-Cespedes, Jean-Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio Wistuba, Pan-Chyr Yang, Denise Aberle, Christian Brambilla, Douglas Flieder, Wilbur Franklin, Adi Gazdar, Michael Gould, Philip Hasleton, Douglas Henderson, Bruce Johnson, David Johnson, Keith Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming Tsao, David Yankelewitz. (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology 6:2, 244-285
CrossRef371
David F. Heigener, Martin Reck. (2011) Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib. Advances in Therapy 28:2, 126-133
CrossRef372
Wendy A Cooper, Sandra OʼToole, Michael Boyer, Lisa Horvath, Annabelle Mahar. (2011) Whatʼs new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 43:2, 103-115
CrossRef373
F. Giraud, L. Greillier. (2011) Oncologie. Revue des Maladies Respiratoires Actualités 3:1, 40-48
CrossRef374
Sarah C. Sim, Magnus Ingelman-Sundberg. (2011) Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends in Pharmacological Sciences 32:2, 72-81
CrossRef375
Christine M. Lovly, David P. Carbone. (2011) Lung cancer in 2010: One size does not fit all. Nature Reviews Clinical Oncology 8:2, 68-70
CrossRef376
Zengliu Su. (2011) Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?. Thoracic Cancer 2:1, 1-6
CrossRef377
L.C. Heukamp, J. Wolf, R. Büttner. (2011) Molekulardiagnostik zur Therapiestratifizierung des Lungenkarzinoms. Der Internist 52:2, 146-154
CrossRef378
Takayuki Shiroyama, Kiyoshi Komuta, Fumio Imamura, Tomonori Hirashima, Takashi Kijima, Isao Tachibana, Ichiro Kawase. (2011) Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer
CrossRef379
N. Okayama, M. Nishioka, S. Hazama, K. Sakai, Y. Suehiro, M. Maekawa, J.-i. Sakamoto, S. Iwamoto, T. Kato, H. Mishima, M. Oka, Y. Hinoda. (2011) The Importance of Evaluation of DNA Amplificability in KRAS Mutation Testing with Dideoxy Sequencing using Formalin-fixed and Paraffin-embedded Colorectal Cancer Tissues. Japanese Journal of Clinical Oncology 41:2, 165-171
CrossRef380
Feero, W. Gregory, Guttmacher, Alan E., , McDermott, Ultan, Downing, James R., Stratton, Michael R., . (2011) Genomics and the Continuum of Cancer Care. New England Journal of Medicine 364:4, 340-350
Full Text381
B Basu, D Olmos, J S de Bono. (2011) Targeting IGF-1R: throwing out the baby with the bathwater?. British Journal of Cancer 104:1, 1-3
CrossRef382
Geoffrey Y Ku, Gilberto de Lima Jopes Jr. (2011) EML4-ALK in non-small-cell lung cancer: the breathtaking progress from benchtop to Phase III clinical trial. Therapy 8:1, 55-61
CrossRef383
Roland Penzel, Christine Sers, Yuan Chen, Ulrich Lehmann-Mühlenhoff, Sabine Merkelbach-Bruse, Andreas Jung, Thomas Kirchner, Reinhard Büttner, Hans H. Kreipe, Iver Petersen, Manfred Dietel, Peter Schirmacher. (2011) EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Archiv 458:1, 95-98
CrossRef384
Davide Tassinari, Sergio Sartori, Maximilian Papi, Fabrizio Drudi, Cinzia Castellani, Federica Carloni, Paola Tombesi, Luigi Lazzari-Agli. (2011) Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach. Oncology 80:5-6, 350-358
CrossRef385
Kamila Wojas-Krawczyk, Paweł Krawczyk, Radosław Mlak, Tomasz Kucharczyk, Dariusz M. Kowalski, Maciej Krzakowski, Janusz Milanowski. (2011) The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients. Respiration 82:4, 341-350
CrossRef386
Cesar A. Perez, Edgardo S. Santos, Belisario A. Arango, Luis E. Raez, Ezra E. W. Cohen, David W. Eisele. (2011) Novel molecular targeted therapies for refractory thyroid cancer. Head & Neckn/a-n/a
CrossRef387
Gustavo Baretton, Stephan Grabbe, Ulrich Keilholz, Guido Sauter. (2011) Molekulare Diagnostik und Therapie in der Onkologie. Onkologie 34:s2, 5-9
CrossRef388
Edgardo S Santos. (2011) New discoveries in lung cancer biology: paving the road of personalized medicine. Therapy 8:1, 1-4
CrossRef389
Rex Chin Wei Yung, Susan Otell, Peter Illei, Douglas P. Clark, David Feller-Kopman, Lonny Yarmus, Frederic Askin, Edward Gabrielson, Qing Kay Li. (2011) Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer Cytopathologyn/a-n/a
CrossRef390
Seung Tae Kim, Yoon Ji Choi, Kyong Hwa Park, Sang Cheul Oh, Jae Hong Seo, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim. (2011) Epidermal Growth Factor Receptor Mutations as a Prognostic Factor in Korean Patients with Advanced Lung Adenocarcinoma Who Had Not Been Treated with Received Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Chemotherapy 57:2, 108-114
CrossRef391
Thomas E. Stinchcombe, Mark A. Socinski. (2011) Maintenance Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 174-182
CrossRef392
Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. (2011) Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer 117:1, 143-151
CrossRef393
Wen-Chien Fan, Chong-Jen Yu, Chun-Ming Tsai, Ming-Shyan Huang, Chun-Liang Lai, Te-Chun Hsia, Yin-Jing Tien, Shiang-Fen Huang, Chieh-Hung Wu, Kun-Ta Chou, Yu-Chin Lee, Reury-Perng Perng, Yuh-Min Chen. (2011) Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 148-155
CrossRef394
Hee Joung Kim, Wan Seop Kim, Kyeong-Cheol Shin, Gwan Ho Lee, Mi-Jin Kim, Jeong Eun Lee, Kyu Sang Song, Sun Young Kim, Kye Young Lee. (2011) Comparative Analysis of Peptide Nucleic Acid (PNA)-Mediated Real-Time PCR Clamping and DNA Direct Sequencing for EGFR Mutation Detection. Tuberculosis and Respiratory Diseases 70:1, 21
CrossRef395
Fumihiko Hirai, Kaname Nosaki, Taro Ohba, Takuro Kometani, Masafumi Yamaguchi, Motoharu Hamatake, Takashi Seto, Kenji Sugio, Yukito Ichinose. (2011) A Retrospective Study of Feasibility of Third-line or Higher Chemotherapy Using Pemetrexed in Non-squamous, Non-small Cell Lung Cancer Patients. Haigan 51:4, 227-232
CrossRef396
Renhua Guo, Xiaofen Chen, Tongshan Wang, Zhiyuan Zhang, Jin Sun, Yongqian Shu. (2011) Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 11:1, 90
CrossRef397
Timothy A. Yap, Shahneen K. Sandhu, Craig P. Carden, Johann S. de Bono. (2011) Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA: A Cancer Journal for Clinicians 61:1, 31-49
CrossRef398
Katsuhiro Masago, Shiro Fujita, Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Yuichi Sakamori, Tadashi Mio, Michiaki Mishima. (2011) Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy. Clinical Lung Cancer 12:1, 56-61
CrossRef399
Ming-Sound Tsao, Akira Sakurada, Keyue Ding, Sarit Aviel-Ronen, Olga Ludkovski, Ni Liu, Aurélie Le Maître, David Gandara, David H. Johnson, James R. Rigas, Lesley Seymour, Frances A. Shepherd. (2011) Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 139-147
CrossRef400
Tatsuya Nagano, Yoshikazu Kotani, Kazuyuki Kobayashi, Masahiro Katsurada, Yukihisa Hatakeyama, Suya Hori, Daisuke Tamura, Daisuke Kasai, Yasuhiro Funada, Yoshihiro Nishimura. (2011) Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib. Case Reports in Pulmonology 2011, 1-4
CrossRef401
Magali Olivier, Philippe Taniere. (2011) Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Current Opinion in Oncology 23:1, 88-92
CrossRef402
Katey S. S. Enfield, Greg L. Stewart, Larissa A. Pikor, Carlos E. Alvarez, Stephen Lam, Wan L. Lam, Raj Chari. (2011) MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer. Journal of Biomedicine and Biotechnology 2011, 1-15
CrossRef403
Laurent Becquemont, Ana Alfirevic, Ursula Amstutz, Hiltrud Brauch, Evelyne Jacqz-Aigrain, Pierre Laurent-Puig, Miguel A Molina, Mikko Niemi, Matthias Schwab, Andrew A Somogyi, Eric Thervet, Anke-Hilse Maitland-van der Zee, André BP van Kuilenburg, Ron HN van Schaik, Céline Verstuyft, Mia Wadelius, Ann K Daly. (2011) Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12:1, 113-124
CrossRef404
Mark D. Vincent. 2011. Cancer: Beyond Speciation. , 283-350.
CrossRef405
William Pao, A John Iafrate, Zengliu Su. (2011) Genetically informed lung cancer medicine. The Journal of Pathology 223:2, 231-241
CrossRef406
Erika Taube, Elina Jokinen, Peppi Koivunen, Jussi P. Koivunen. (2011) A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. International Journal of Cancern/a-n/a
CrossRef407
Thomas E. Stinchcombe, Maria Q. Baggstrom, Neeta Somaiah, George R. Simon, Ramaswamy Govindan. (2011) Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology. Journal of Thoracic Oncology 6:1, 227-232
CrossRef408
Shingo Miyamoto, Yusuke Okuma, Yusuke Takagi, Tsuneo Shimokawa, Yukio Shimokawa, Mari Iguchi, Tatsuru Okamura, Masahiko Shibuya. (2011) Continuous treatment with EGFR-TKI in the terminal stage for non-small cell lung cancer patients who initially responded to EGFR-TKI. Palliative Care Research 6:1, 119-125
CrossRef409
Anastasios Dimou, Kevin Harrington, Kostas N. Syrigos. (2011) From the Bench to Bedside: Biological and Methodology Considerations for the Future of Companion Diagnostics in Nonsmall Cell Lung Cancer. Pathology Research International 2011, 1-8
CrossRef410
J. Matthew Reinersman, Melissa L. Johnson, Gregory J. Riely, Dhananjay A. Chitale, Anthony D. Nicastri, Gerald A. Soff, Ann G. Schwartz, Camelia S. Sima, Getinet Ayalew, Christopher Lau, Maureen F. Zakowski, Valerie W. Rusch, Marc Ladanyi, Mark G. Kris. (2011) Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. Journal of Thoracic Oncology 6:1, 28-31
CrossRef411
Julie R. Brahmer, Suzanne E. Dahlberg, Robert J. Gray, Joan H. Schiller, Michael C. Perry, Alan Sandler, David H. Johnson. (2011) Sex Differences in Outcome with Bevacizumab Therapy. Journal of Thoracic Oncology 6:1, 103-108
CrossRef412
Raffaele Costanzo, Maria Carmela Piccirillo, Claudia Sandomenico, Guido Carillio, Agnese Montanino, Gennaro Daniele, Pasqualina Giordano, Jane Bryce, Gianfranco De Feo, Massimo Di Maio, Gaetano Rocco, Nicola Normanno, Francesco Perrone, Alessandro Morabito. (2011) Gefitinib in Non Small Cell Lung Cancer. Journal of Biomedicine and Biotechnology 2011, 1-14
CrossRef413
George R. Collins, Jaiyeola Thomas, Neelam Joshi, Songlin Zhang. (2011) The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms. Cancer Cytopathologyn/a-n/a
CrossRef414
Noriaki Sunaga, Hisao Imai, Kimihiro Shimizu, David S. Shames, Seiichi Kakegawa, Luc Girard, Mitsuo Sato, Kyoichi Kaira, Tamotsu Ishizuka, Adi F. Gazdar, John D. Minna, Masatomo Mori. (2011) Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. International Journal of Cancern/a-n/a
CrossRef415
Chia-Chi Lin, James Chih-Hsin Yang. (2011) Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations. Drugs 71:1, 79-88
CrossRef416
Alex Chang. (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71:1, 3-10
CrossRef417
Dong-Wan Kim, Se-Hoon Lee, Jong Seok Lee, Myung Ah Lee, Jin Hyoung Kang, Si Young Kim, Sang Won Shin, Hoon-Kyo Kim, Dae Seog Heo. (2011) A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer 71:1, 65-69
CrossRef418
Mi Young Cha, Kwang-Ok Lee, Mira Kim, Ji Yeon Song, Kyu Hang Lee, Jongmin Park, Yun Jung Chae, Young Hoon Kim, Kwee Hyun Suh, Gwan Sun Lee, Seung Bum Park, Maeng Sup Kim. (2011) Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. International Journal of Cancern/a-n/a
CrossRef419
Takahiro Nakajima, Kazuhiro Yasufuku. (2011) How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. Journal of Thoracic Oncology 6:1, 203-206
CrossRef420
Walter Lehmacher, Stephanie Wolff. (2011) Die Bedeutung von Head-to-Head-Studien für die versorgungsnahe klinische Forschung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 105:9, 639-645
CrossRef421
George Bouliotis, Lucinda Billingham. (2011) Crossing survival curves: alternatives to the log-rank test. Trials 12:Suppl 1, A137
CrossRef422
Gérard Zalcman, Emmanuel Bergot, Christian Creveuil, Guénaëlle Levallet, Emmanuèle Lechapt. (2011) Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. Current Opinion in Oncology 23:1, 106-111
CrossRef423
Shigeo Kawase, Noboru Hattori, Nobuhisa Ishikawa, Yasushi Horimasu, Kazunori Fujitaka, Osamu Furonaka, Takeshi Isobe, Seigo Miyoshi, Hironobu Hamada, Takashi Yamane, Akihito Yokoyama, Nobuoki Kohno. (2011) Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respiratory Research 12:1, 97
CrossRef424
David F. Heigener. (2011) Non-Small Cell Lung Cancer in Never-Smokers: A New Disease Entity?. Onkologie 34:4, 202-207
CrossRef425
Yuichi Takiguchi, Takashi Seto, Yukito Ichinose, Naoyuki Nogami, Tetsu Shinkai, Hiroaki Okamoto, Koichi Minato, Nobuhiko Seki, Kenji Eguchi, Kazuma Kishi, Masanori Nishikawa, Koshiro Watanabe. (2011) Long-Term Administration of Second-Line Chemotherapy with S-1 and Gemcitabine for Platinum-Resistant Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 156-160
CrossRef426
Bruno R Bastos, Rogerio C Lilenbaum. (2011) Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. Therapy 8:1, 9-14
CrossRef427
Hong-Joon Shin, Tae-Ok Kim, Hyun-Wook Kang, Su-Young Chi, Hee-Jung Ban, Soo-Ok Kim, Yong-Soo Kwon, In-Jae Oh, Kyu-Sik Kim, Yu-Il Kim, Sung-Chul Lim, Young-Chul Kim. (2011) Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. Tuberculosis and Respiratory Diseases 71:1, 15
CrossRef428
Kwok-Chi LAM, Tony S. MOK. (2011) Targeted therapy: An evolving world of lung cancer. Respirology 16:1, 13-21
CrossRef429
Max Dahele, Suresh Senan. (2011) The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms. Cancer Research and Treatment 43:2, 75
CrossRef430
Fumiko Tokuhashi, Shinji Sakaguchi, Kazutoshi Isobe, Keishi Sugino, Tsutomu Hatori, Sakae Homma. (2011) An Autopsied Case of Lung Cancer Which Simultaneously Expressed L858R and T790M Mutations Before Gefitinib Therapy. Haigan 51:2, 84-88
CrossRef431
Irene Centeno, Pilar Blay, Iñigo Santamaría, Aurora Astudillo, Ana S Pitiot, Fernando G Osorio, Patricia González-Arriaga, Fernando Iglesias, Primitiva Menéndez, Adonina Tardón, Jose M Freije, Milagros Balbín. (2011) Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: A novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer 11:1, 172
CrossRef432
Haruhiko Nakamura, Koji Ando, Takuo Shinmyo, Katsuhiko Morita, Atsushi Mochizuki, Noriaki Kurimoto, Shinobu Tatsunami. (2011) Female Gender Is an Independent Prognostic Factor in Non-small-cell Lung Cancer: A Meta-analysis. Annals of Thoracic and Cardiovascular Surgery 17:5, 469-480
CrossRef433
Jesús García-Foncillas, Pilar Garrido, Javier Gómez, José Palacios, Miquel Tarón. (2011) Recomendaciones para la determinación de las mutaciones del gen EGFR en el carcinoma de pulmón no microcítico. Revista Española de Patología 44:1, 17-31
CrossRef434
Christos Katsios, Dimosthenis E Ziogas, Dimitrios H Roukos. (2011) New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology. Expert Review of Anticancer Therapy 11:1, 5-8
CrossRef435
Federico Longo, Alejandro Riquelme, Mercedes Rodríguez, María E. Olmedo, Pilar Garrido. (2011) Long-Term Survival in a Smoking Caucasian Male Patient Treated with Gefitinib for Spinal Cord Compression Secondary to Lung Cancer. Onkologie 34:6, 326-328
CrossRef436
D. L. Aisner, C. Deshpande, Z. Baloch, C. D. Watt, L. A. Litzky, B. Malhotra, A. R. Sepulveda, C. Langer, T. Evans, V. M. Van Deerlin. (2011) Evaluation of EGFR mutation status in cytology specimens: An institutional experience. Diagnostic Cytopathologyn/a-n/a
CrossRef437
Marta Salido, Lara Pijuan, Luz Martínez-Avilés, Ana B. Galván, Israel Cañadas, Ana Rovira, Montserrat Zanui, Alejandro Martínez, Raquel Longarón, Francisco Sole, Sergio Serrano, Beatriz Bellosillo, Murry W. Wynes, Joan Albanell, Fred R. Hirsch, Edurne Arriola. (2011) Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 21-27
CrossRef438
Takeshi Honda, Haruhiro Saito, Shuji Murakami, Chikako Hasegawa, Takeshi Isobe, Kouzo Yamada. (2011) A Case of Advanced Lung Adenocarcinoma with Paranasal Sinus Metastases, in Which Gefitinib Was Effective as First-line Therapy and Cyberknife® Was Efficacious for Local Control. Haigan 51:1, 5-10
CrossRef439
Zengliu Su, Dora Dias-Santagata, MarKeesa Duke, Katherine Hutchinson, Ya-Lun Lin, Darrell R. Borger, Christine H. Chung, Pierre P. Massion, Cindy L. Vnencak-Jones, A. John Iafrate, William Pao. (2011) A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer. The Journal of Molecular Diagnostics 13:1, 74-84
CrossRef440
A. Bearz, M. Berretta, A. Lleshi, U. Tirelli. (2011) Target Therapies in Lung Cancer. Journal of Biomedicine and Biotechnology 2011, 1-5
CrossRef441
Jill E. Larsen, Tina Cascone, David E. Gerber, John V. Heymach, John D. Minna. (2011) Targeted Therapies for Lung Cancer. The Cancer Journal 17:6, 512-527
CrossRef442
Hayato KONNO, Taku NAKAGAWA, Tomohiko SASAKI, Norio OYAMA, Yoshiyuki UESAKA, Masahiro SAITO. (2011) A CASE OF LUNG CANCER DEVELOPED PNEUMOTHORAX DURING ADMINISTRATION OF GEFITINIB. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 72:1, 43-48
CrossRef443
Marc Ladanyi, Pancras CW Hogendoorn. (2011) Cancer biology and genomics: translating discoveries, transforming pathology. The Journal of Pathology 223:2, 99-101
CrossRef444
Hye Ryun Kim, Hyo Sup Shim, Jin-Haeng Chung, Young Joo Lee, Yun Kyoung Hong, Sun Young Rha, Se Hoon Kim, Sang-Jun Ha, Se Kyu Kim, Kyung Young Chung, Ross Soo, Joo Hang Kim, Byoung Chul Cho. (2011) Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancern/a-n/a
CrossRef445
K-J Franke, C Bruckner, G Nilius, K-H Ruhle. (2011) Investigation of the flexibility of bronchoscopes. European Journal of Medical Research 16:9, 420
CrossRef446
Guanghui Gao, Shengxiang Ren, Aiwu Li, Jianfang Xu, Qinghua Xu, Chunxia Su, Jian Guo, Qinfang Deng, Caicun Zhou. (2011) Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from 6 phase III randomized controlled trials. International Journal of Cancern/a-n/a
CrossRef447
Sodai Narumi, Akira Inoue, Taizo Shibahara, Ryotaro Igusa, Tomohiro Sakakibara, Toshihiro Nukiwa. (2011) A Case of Small-cell Lung Carcinoma with EGFR Gene Mutation. Haigan 51:7, 798-802
CrossRef448
Bryan Corrin, Andrew G. Nicholson. 2011. Tumours. , 531-705.
CrossRef449
Gilberto de Lima Lopes, Joel E. Segel, Daniel S. W. Tan, Young K. Do, Tony Mok, Eric A. Finkelstein. (2011) Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancern/a-n/a
CrossRef450
L.T. Tanoue. (2011) Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. Yearbook of Pulmonary Disease 2011, 93-95
CrossRef451
Gilda da Cunha Santos, Ni Liu, Ming-Sound Tsao, Suzanne Kamel-Reid, Kayu Chin, William R. Geddie. (2010) Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards. Cancer Cytopathology 118:6, 450-456
CrossRef452
J. Weiss, M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schottle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansen, D. Rauh, I. Baessmann, J. Altmuller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sanger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nurnberg, S. Perner, R. K. Thomas. (2010) Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine 2:62, 62ra93-62ra93
CrossRef453
N. C. Turner, M. J. Seckl. (2010) A Therapeutic Target for Smoking-Associated Lung Cancer. Science Translational Medicine 2:62, 62ps56-62ps56
CrossRef454
Sabine Klüter , Jeffrey R. Simard , Haridas B. Rode, Christian Grütter, Vijaykumar Pawar, Hans C. A. Raaijmakers, Tjeerd A. Barf, Matthias Rabiller, Willem A. L. van Otterlo , Daniel Rauh . (2010) Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance. ChemBioChem 11:18, 2557-2566
CrossRef455
Shinji Mizuarai, Hidehito Kotani. (2010) Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Human Genetics 128:6, 567-575
CrossRef456
Philip Bonomi. (2010) Epidermal Growth Factor Receptor Pathway. Journal of Thoracic Oncology 5, S470-S471
CrossRef457
A. Soltermann, I. Opitz, V. Tischler, S. Thies, L. Morra, R. A. Stahel, W. Weder, H. Moch. (2010) EMT in NSCLC and malignant pleural mesothelioma. memo - Magazine of European Medical Oncology 3:4, 180-184
CrossRef458
Joel W Neal. (2010) The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncology 6:12, 1827-1832
CrossRef459
Tokujiro Yano, Akira Haro, Tsukihisa Yoshida, Yosuke Morodomi, Kensaku Ito, Yasunori Shikada, Fumihiro Shoji, Riichiroh Maruyama, Yoshihiko Maehara. (2010) Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. Journal of Surgical Oncology 102:7, 852-855
CrossRef460
Constantine Alifrangis, Michael J Seckl. (2010) Genetics of gestational trophoblastic neoplasia: an update for the clinician. Future Oncology 6:12, 1915-1923
CrossRef461
Shirish M. Gadgeel, Michele L. Cote, Ann G. Schwartz, Larry H. Matherly, Antoinette Wozniak, Gerold Bepler. (2010) Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resistance Updates 13:6, 196-204
CrossRef462
Young Joo Lee, Hyo Sub Shim, Young Ae Kang, Su Jung Hong, Hyun Ki Kim, Hoguen Kim, Se Kyu Kim, Sung Ho Choi, Joo-Hang Kim, Byoung Chul Cho. (2010) Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 136:12, 1937-1944
CrossRef463
Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat H. Ansari, Michael Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeifer, Thomas A. Marsland, Goetz H. Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Claire Beadman, Mark A. Socinski. (2010) Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1977-1985
CrossRef464
James F. Spicer, Sarah M. Rudman. (2010) EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Targeted Oncology 5:4, 245-255
CrossRef465
Gopa Iyer, Matthew I Milowsky, Dean F Bajorin. (2010) Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy 10:12, 1917-1932
CrossRef466
Rafael Rosell, Alain Vergnenegre, Baorui Liu, Manuel Cobo, Bartomeu Massuti, Jia Wei, Miguel Angel Molina, Carlota Costa, Cristina Queralt, Miquel Taron. (2010) Biomarkers in lung oncology. Pulmonary Pharmacology & Therapeutics 23:6, 508-514
CrossRef467
David R. Gandara, Peter Grimminger, Philip C. Mack, Primo N. Lara, Tianhong Li, Peter V. Danenberg, Kathleen D. Danenberg. (2010) Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1933-1938
CrossRef468
Toshihiro Yamashita, Hidetaka Uramoto, Takamitsu Onitsuka, Kenji Ono, Tetsuro Baba, Tetsuya So, Tomoko So, Mitsuhiro Takenoyama, Takeshi Hanagiri, Tsunehiro Oyama, Kosei Yasumoto. (2010) Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70:3, 320-328
CrossRef469
K. L. Aung, R. E. Board, G. Ellison, E. Donald, T. Ward, G. Clack, M. Ranson, A. Hughes, W. Newman, C. Dive. (2010) Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. The HUGO Journal 4:1-4, 11-21
CrossRef470
Jean-François Morère, Jeanne-Marie Bréchot, Virginie Westeel, Valerie Gounant, Bernard Lebeau, Fabien Vaylet, Fabrice Barlési, Thierry Urban, Pierre-Jean Souquet, Didier Debieuvre, Laurence Baudrin, Gérard Zalcman, Franck Morin, Bernard Milleron, Denis Moro-Sibilot. (2010) Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 70:3, 301-307
CrossRef471
Jean-François Morère. (2010) Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality. Targeted Oncology 5:4, 229-230
CrossRef472
Yoon Hee Choi, Jin Kyung Lee, Hye Jin Kang, Tae Sup Lee, Hye-Ryoun Kim, Cheol Hyeon Kim, Jae Soo Koh, Hee Jong Baek, Jae Cheol Lee, Im Il Na. (2010) Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1949-1952
CrossRef473
Tomoyuki Hishida, Kanji Nagai, Tetsuya Mitsudomi, Kohei Yokoi, Haruhiko Kondo, Hirohisa Horinouchi, Hirohiko Akiyama, Takeshi Nagayasu, Masahiro Tsuboi. (2010) Salvage surgery for advanced non–small cell lung cancer after response to gefitinib. The Journal of Thoracic and Cardiovascular Surgery 140:5, e69-e71
CrossRef474
Claire Watkins, Yuri Rukazenkov. (2010) Response to ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’
(Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69). Journal of Cellular and Molecular Medicine 14:11, 2693-2694
CrossRef475
Giuseppe Bronte, Sergio Rizzo, Laura La Paglia, Vincenzo Adamo, Sergio Siragusa, Corrado Ficorella, Daniele Santini, Viviana Bazan, Giuseppe Colucci, Nicola Gebbia, Antonio Russo. (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews 36, S21-S29
CrossRef476
Ronan J. Kelly, Colleen Darnell, Olivier Rixe. (2010) Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity. The Cancer Journal 16:6, 635-642
CrossRef477
Karl Kieburtz. (2010) Discovering Neuroprotection in Parkinson's Disease, or Getting to Haphazard. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:6, 700-706
CrossRef478
William Pao, Juliann Chmielecki. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 10:11, 760-774
CrossRef479
Joel W. Neal, Rebecca S. Heist, Panos Fidias, Jennifer S. Temel, Mark Huberman, J. Paul Marcoux, Alona Muzikansky, Thomas J. Lynch, Lecia V. Sequist. (2010) Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology 5:11, 1855-1858
CrossRef480
Nagahiro Saijo. (2010) Targeted therapies: Tyrosine-kinase inhibitors—new standard for NSCLC therapy. Nature Reviews Clinical Oncology 7:11, 618-619
CrossRef481
Geoffrey Y. Ku, Akhil Chopra, Gilberto de Lima Lopes. (2010) Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer 70:2, 223-225
CrossRef482
Mark Clemons, Anil A. Joy, Radhi Abdulnabi, Mauricio Kotliar, Jodi Lynch, Johan P. Jordaan, Neill Iscoe, Karen Gelmon. (2010) Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. Breast Cancer Research and Treatment 124:1, 177-186
CrossRef483
Amanda Psyrri, Barbara Burtness. (2010) Targeted therapies: Molecular selection for 'smart' study design in lung cancer. Nature Reviews Clinical Oncology 7:11, 621-622
CrossRef484
Christos Katsios, Odysseas Zoras, Dimitrios H Roukos. (2010) Improving women’s health: advances, failures and cancer genome prospects. Women's Health 6:6, 769-772
CrossRef485
A. F. Eichler, K. T. Kahle, D. L. Wang, V. A. Joshi, H. Willers, J. A. Engelman, T. J. Lynch, L. V. Sequist. (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology 12:11, 1193-1199
CrossRef486
José Manuel Trigo Pérez, Pilar Garrido López, Enriqueta Felip Font, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clinical and Translational Oncology 12:11, 735-741
CrossRef487
Benjamin Levy, Alexander Drilon, KarLeung Siu, Michael Grossbard. (2010) Extended-Duration Therapy in Advanced Non–Small-Cell Lung Cancer: Promise and Pitfalls. Clinical Lung Cancer 11:6, 383-390
CrossRef488
Christos Katsios, Dimosthenis E. Ziogas, Theodore Liakakos, Odysseas Zoras, Dimitrios H. Roukos. (2010) Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice. Journal of Surgical Research
CrossRef489
Choi, Young Lim, Soda, Manabu, Yamashita, Yoshihiro, Ueno, Toshihide, Takashima, Junpei, Nakajima, Takahiro, Yatabe, Yasushi, Takeuchi, Kengo, Hamada, Toru, Haruta, Hidenori, Ishikawa, Yuichi, Kimura, Hideki, Mitsudomi, Tetsuya, Tanio, Yoshiro, Mano, Hiroyuki, . (2010) EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine 363:18, 1734-1739
Full Text490
Butrynski, James E., D'Adamo, David R., Hornick, Jason L., Dal Cin, Paola, Antonescu, Cristina R., Jhanwar, Suresh C., Ladanyi, Marc, Capelletti, Marzia, Rodig, Scott J., Ramaiya, Nikhil, Kwak, Eunice L., Clark, Jeffrey W., Wilner, Keith D., Christensen, James G., Jänne, Pasi A., Maki, Robert G., Demetri, George D., Shapiro, Geoffrey I., . (2010) Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor. New England Journal of Medicine 363:18, 1727-1733
Full Text491
Kwak, Eunice L., Bang, Yung-Jue, Camidge, D. Ross, Shaw, Alice T., Solomon, Benjamin, Maki, Robert G., Ou, Sai-Hong I., Dezube, Bruce J., Jänne, Pasi A., Costa, Daniel B., Varella-Garcia, Marileila, Kim, Woo-Ho, Lynch, Thomas J., Fidias, Panos, Stubbs, Hannah, Engelman, Jeffrey A., Sequist, Lecia V., Tan, WeiWei, Gandhi, Leena, Mino-Kenudson, Mari, Wei, Greg C., Shreeve, S. Martin, Ratain, Mark J., Settleman, Jeffrey, Christensen, James G., Haber, Daniel A., Wilner, Keith, Salgia, Ravi, Shapiro, Geoffrey I., Clark, Jeffrey W., Iafrate, A. John, . (2010) Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine 363:18, 1693-1703
Full Text492
F Oshita, M Ohe, T Honda, S Murakami, T Kondo, H Saito, K Noda, K Yamashita, Y Nakayama, K Yamada. (2010) Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. British Journal of Cancer 103:9, 1325-1330
CrossRef493
P. Wheatley-Price, F. Blackhall, S.- M. Lee, C. Ma, L. Ashcroft, M. Jitlal, W. Qian, A. Hackshaw, R. Rudd, R. Booton, S. Danson, P. Lorigan, N. Thatcher, F. A. Shepherd. (2010) The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Annals of Oncology 21:10, 2023-2028
CrossRef494
Matthew Meyerson, Stacey Gabriel, Gad Getz. (2010) Advances in understanding cancer genomes through second-generation sequencing. Nature Reviews Genetics 11:10, 685-696
CrossRef495
E. Felip, S. Cedres, E. Checa, P. Martinez. (2010) How to integrate current knowledge in selecting patients for first line in NSCLC?. Annals of Oncology 21:Supplement 7, vii230-vii233
CrossRef496
Tony S Mok, Qing Zhou, Linda Leung, Herbert H Loong. (2010) Personalized medicine for non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1601-1611
CrossRef497
Gelenis Domingo, Cesar A Perez, Michel Velez, Jennifer Cudris, Luis E Raez, Edgardo S Santos. (2010) EGF receptor in lung cancer: a successful story of targeted therapy. Expert Review of Anticancer Therapy 10:10, 1577-1587
CrossRef498
Yasufumi Kato, Nir Peled, Murry W. Wynes, Koichi Yoshida, Marta Pardo, Celine Mascaux, Tatsuo Ohira, Masahiro Tsuboi, Jun Matsubayashi, Toshitaka Nagao, Norihiko Ikeda, Fred R. Hirsch. (2010) Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1551-1558
CrossRef499
Sandra Geiger, Marcus Schlemmer, Volker Heinemann, Hans Joachim Stemmler. (2010) Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. Anti-Cancer Drugs 21:9, 799-804
CrossRef500
E. De Maio, C. Tibaldi, A. D'Incecco, S. Bursi, C. Barbara, S. Cupini, R. Di Marsico, M. D'Arcangelo, L. Landi, G. Minuti, F. Cappuzzo. (2010) Consequences of targeted treatments for second-line therapy. Annals of Oncology 21:Supplement 7, vii234-vii240
CrossRef501
Marius I. Ilie, Véronique Hofman, Christelle Bonnetaud, Katia Havet, Virginie Lespinet-Fabre, Céline Coëlle, Virginie Gavric-Tanga, Nicolas Vénissac, Jerôme Mouroux, Paul Hofman. (2010) Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Archiv 457:4, 483-495
CrossRef502
Martin Reck, Nico van Zandwijk, Cesare Gridelli, Zoltan Baliko, Danny Rischin, Simon Allan, Maciej Krzakowski, David Heigener. (2010) Erlotinib in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1616-1622
CrossRef503
Tony Mok, Yi-long Wu, Joseph Siu-kie Au, Caicun Zhou, Li Zhang, Reury-Perng Perng, Keunchil Park. (2010) Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1609-1615
CrossRef504
Wilfried Eberhardt. (2010) Compassionate Use Programs or Phase IV Trials of Innovative Molecular Targeted Drugs in Lung Cancer. Journal of Thoracic Oncology 5:10, 1495-1497
CrossRef505
Akito Hata, Hiroshige Yoshioka, Shiro Fujita, Kei Kunimasa, Reiko Kaji, Yukihiro Imai, Keisuke Tomii, Masahiro Iwasaku, Akihiro Nishiyama, Tadashi Ishida, Nobuyuki Katakami. (2010) Complex Mutations in the Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1524-1528
CrossRef506
Rafael Rosell, Teresa Moran, Felipe Cardenal, Rut Porta, Santiago Viteri, Miguel Angel Molina, Susana Benlloch, Miquel Taron. (2010) Predictive biomarkers in the management of EGFR mutant lung cancer. Annals of the New York Academy of Sciences 1210:1, 45-52
CrossRef507
Olga C. J. Schuurbiers, Monika G. Looijen-Salamon, Marjolijn J. L. Ligtenberg, Henricus F. M. van der Heijden. (2010) A Brief Retrospective Report on the Feasibility of Epidermal Growth Factor Receptor and KRAS Mutation Analysis in Transesophageal Ultrasound- and Endobronchial Ultrasound-Guided Fine Needle Cytological Aspirates. Journal of Thoracic Oncology 5:10, 1664-1667
CrossRef508
Charles Swanton, Carlos Caldas. (2010) From genomic landscapes to personalized cancer management-is there a roadmap?. Annals of the New York Academy of Sciences 1210:1, 34-44
CrossRef509
Marta Batus, Mary Jo Fidler, Philip D Bonomi. (2010) Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1589-1599
CrossRef510
Robert Pirker, Felix J. F. Herth, Keith M. Kerr, Martin Filipits, Miquel Taron, David Gandara, Fred R. Hirsch, Dominique Grunenwald, Helmut Popper, Egbert Smit, Manfred Dietel, Antonio Marchetti, Christian Manegold, Peter Schirmacher, Michael Thomas, Rafael Rosell, Federico Cappuzzo, Rolf Stahel. (2010) Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1706-1713
CrossRef511
Katharine A. Price, Christopher G. Azzoli, Lee M. Krug, Maria C. Pietanza, Naiyer A. Rizvi, William Pao, Mark G. Kris, Gregory J. Riely, Robert T. Heelan, Maria E. Arcila, Vincent A. Miller. (2010) Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, 1623-1629
CrossRef512
J. S. de Bono, Alan Ashworth. (2010) Translating cancer research into targeted therapeutics. Nature 467:7315, 543-549
CrossRef513
Victor Cohen, Jason S. Agulnik, Celina Ang, Goulnar Kasymjanova, Gerald Batist, David Small, Guilherme Brandao, George Chong, Wilson H. Miller. (2010) Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer. Cancer 116:18, 4309-4317
CrossRef514
Annemarie Becker, Atie van Wijk, Egbert F. Smit, Pieter E. Postmus. (2010) Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:9, 1477-1480
CrossRef515
Kyu-Pyo Kim, Sang-We Kim. (2010) Chemotherapy for advanced non-small-cell lung cancer patients with poor performance. Expert Review of Clinical Pharmacology 3:5, 623-626
CrossRef516
Yin-Hsun Feng, Chao-Jung Tsao, Chao-Liang Wu, Jan-Gowth Chang, Pei-Jung Lu, Kun-Tu Yeh, Gia-Shing Shieh, Ai-Li Shiau, Jeng-Chang Lee. (2010) Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Science 101:9, 2033-2038
CrossRef517
Haiying Cheng, Xunhai Xu, Daniel B. Costa, Charles A. Powell, Balazs Halmos. (2010) Molecular Testing in Lung Cancer: The Time Is Now. Current Oncology Reports 12:5, 335-348
CrossRef518
Sara Caponi, Enrico Vasile, Laura Ginocchi, Carmelo Tibaldi, Francesca Borghi, Armida D'Incecco, Maurizio Lucchesi, Chiara Caparello, Michele Andreuccetti, Alfredo Falcone. (2010) Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All. Clinical Lung Cancer 11:5, 320-327
CrossRef519
Yoichi Nakamura, Kazumi Sano, Hiroshi Soda, Hiroshi Takatani, Minoru Fukuda, Seiji Nagashima, Tomayoshi Hayashi, Mikio Oka, Kazuhiro Tsukamoto, Shigeru Kohno. (2010) Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:9, 1404-1409
CrossRef520
H. Francis, B. Solomon. (2010) The current status of targeted therapy for non-small cell lung cancer. Internal Medicine Journal 40:9, 611-618
CrossRef521
Hubert E. Blum. (2010) Individualized medicine 2010. Journal of Cellular and Molecular Medicine 14:9, 2257-2263
CrossRef522
N. Saijo. (2010) Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy. Japanese Journal of Clinical Oncology 40:9, 855-862
CrossRef523
Fang Wang, Liangping Xia, Guifang Guo, Huijuan Qiu, Feifei Zhou, Bei Zhang, Li Zhang. (2010) Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. The Chinese-German Journal of Clinical Oncology 9:9, 502-506
CrossRef524
Athanasios G. Pallis, Michalis V. Karamouzis, Panagiotis A. Konstantinopoulos, Athanasios G. Papavassiliou. (2010) Molecular networks in respiratory epithelium carcinomas. Cancer Letters 295:1, 1-6
CrossRef525
M. Rodrigues, E. Routier, J.-C. Soria. (2010) Soins spécifiques, soins de support — même combat !. Oncologie 12:9, 555-557
CrossRef526
Chia-Chi Lin, Hsin-Hsin Hsu, Chia-Tung Sun, Jin-Yuan Shih, Zhong-Zhe Lin, Chong-Jen Yu, George G. Chen, Michael Kuan Yew Hsin, Kwok Chi Lam, Linda Leung, Chih-Hsin Yang, Tony Mok. (2010) Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors. Journal of Thoracic Oncology 5:9, 1424-1429
CrossRef527
J.A.D. Ironside, J.F. English, G.R. Kerr, A. Price, F.A. Little, S.C. Erridge, M.J. Mackean. (2010) Three Years of Erlotinib in Routine Practice for Non-small Cell Lung Cancer in South East Scotland. Clinical Oncology 22:7, 550-553
CrossRef528
Paul A. Bunn, Fred R. Hirsch, Robert C. Doebele, D. Ross Camidge, Marileila Varella-Garcia, Wilbur Franklin. (2010) Biomarkers Are Here to Stay for Clinical Research and Standard Care. Journal of Thoracic Oncology 5:8, 1113-1115
CrossRef529
Alessio Squassina, Mirko Manchia, Vangelis G Manolopoulos, Mehmet Artac, Christina Lappa-Manakou, Sophia Karkabouna, Konstantinos Mitropoulos, Maria Del Zompo, George P Patrinos. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11:8, 1149-1167
CrossRef530
Fred R Hirsch, Tony S Mok, Virginia Borges, Paul A Bunn. (2010) Molecularly targeted therapy: when to stop and when to continue?. The Lancet Oncology 11:8, 709-711
CrossRef531
Sandra C Tomaszek, Marianne Huebner, Dennis A Wigle. (2010) Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. Expert Review of Respiratory Medicine 4:4, 499-508
CrossRef532
Thomas E. Stinchcombe, Mark A. Socinski. (2010) Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy. Nature Reviews Clinical Oncology 7:8, 426-428
CrossRef533
Alvin S. Wong, Catherine Teo, Siew-Woon Lim, Eunice Wong, Ross A. Soo, Noreen Chan. (2010) Targeted Therapy at the End of Life for Patients with Lung Cancer. Journal of Palliative Medicine 13:8, 945-948
CrossRef534
Daniel S.-W. Tan, Marco Gerlinger, Bin-Tean Teh, Charles Swanton. (2010) Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer 46:12, 2166-2177
CrossRef535
Daniel Morgensztern, Ramaswamy Govindan. (2010) Best of the Month. Journal of Thoracic Oncology 5:8, 1305-1307
CrossRef536
Robert Pirker. (2010) Bevacizumab in lung cancer: hurdles in clinical development. The Lancet Oncology 11:8, 703-704
CrossRef537
A. Prasse, C. Waller, B. Passlick, J. Müller-Quernheim. (2010) Lungenkrebs aus Sicht der Inneren Medizin und Chirurgie. Der Radiologe 50:8, 662-668
CrossRef538
István Peták, Richárd Schwab, László Őrfi, László Kopper, György Kéri. (2010) Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery 9:7, 523-535
CrossRef539
Jenn-Yu Wu, Chih-Hsin Yang, Ya-Chieh Hsu, Chong-Jen Yu, Shih-Han Chang, Jin-Yuan Shih, Pan-Chyr Yang. (2010) Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:4, 257-263
CrossRef540
Thorvardur R. Halfdanarson, Aminah Jatoi. (2010) Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety. Current Oncology Reports 12:4, 247-252
CrossRef541
Patricia S Kho, Wei Chua, Melissa M Moore, Stephen J Clarke. (2010) Is it prime time for personalized medicine in cancer treatment?. Personalized Medicine 7:4, 387-397
CrossRef542
Stephen L Chan, Tony Mok. (2010) PARP inhibition in BRCA-mutated breast and ovarian cancers. The Lancet 376:9737, 211-213
CrossRef543
Fabien Maldonado, James R Jett. (2010) Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. Current Opinion in Pulmonary Medicine 16:4, 315-320
CrossRef544
Akihiko Kawahara, Koichi Azuma, Satoshi Hattori, Kazutaka Nakashima, Yuji Basaki, Jun Akiba, Sinzo Takamori, Hisamichi Aizawa, Takashi Yanagawa, Hiroto Izumi, Kimitoshi Kohno, Suminori Kono, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono. (2010) The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non–small cell lung cancer. Human Pathology 41:7, 951-959
CrossRef545
Lynette M. Sholl, Neal I. Lindeman. (2010) Molecular Diagnostics Testing for Lung Adenocarcinoma. Pathology Case Reviews 15:4, 103-110
CrossRef546
Shaheenah Dawood. (2010) Novel biomarkers of metastatic cancer. Expert Review of Molecular Diagnostics 10:5, 581-590
CrossRef547
Shih-Chieh Chang, Cheng-Yu Chang, Chiung-Yu Chen, Chong-Jen Yu. (2010) Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia. Journal of Thoracic Oncology 5:7, 1105-1106
CrossRef548
Ariel Lopez-Chavez, Giuseppe Giaccone. (2010) Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nature Reviews Clinical Oncology 7:7, 360-362
CrossRef549
Takaaki Sasaki, Scott J. Rodig, Lucian R. Chirieac, Pasi A. Jänne. (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. European Journal of Cancer 46:10, 1773-1780
CrossRef550
Trevor McKibbin, Wei Zhao, Michael Tagen, Najat C. Daw, Wayne L. Furman, Lisa M. McGregor, J. Russell Geyer, Jeffrey W. Allen, Clinton F. Stewart. (2010) Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. European Journal of Cancer 46:11, 2045-2051
CrossRef551
Albiruni R.A. Razak, Lillian L. Siu, Fei-Fei Liu, Emma Ito, Brian O’Sullivan, Kelvin Chan. (2010) Nasopharyngeal carcinoma: The next challenges. European Journal of Cancer 46:11, 1967-1978
CrossRef552
Francisco A Almeida, Mateen Uzbeck, David Ost. (2010) Initial evaluation of the nonsmall cell lung cancer patient: diagnosis and staging. Current Opinion in Pulmonary Medicine 16:4, 307-314
CrossRef553
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef554
Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma, John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada, Bruce E Johnson. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet Oncology 11:7, 619-626
CrossRef555
Thomas E Stinchcombe, Ramaswamy Govindan. (2010) One more fallen star—ZODIAC and its implications. The Lancet Oncology 11:7, 604-605
CrossRef556
Maemondo, Makoto, Inoue, Akira, Kobayashi, Kunihiko, Sugawara, Shunichi, Oizumi, Satoshi, Isobe, Hiroshi, Gemma, Akihiko, Harada, Masao, Yoshizawa, Hirohisa, Kinoshita, Ichiro, Fujita, Yuka, Okinaga, Shoji, Hirano, Haruto, Yoshimori, Kozo, Harada, Toshiyuki, Ogura, Takashi, Ando, Masahiro, Miyazawa, Hitoshi, Tanaka, Tomoaki, Saijo, Yasuo, Hagiwara, Koichi, Morita, Satoshi, Nukiwa, Toshihiro, . (2010) Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine 362:25, 2380-2388
Full Text557
Thomas Zander, Matthias Scheffler, Sascha Ansen, Jürgen Wolf. (2010) Lungenkrebs: vom Gen zur Therapie. Onkopipeline 3:2, 81-86
CrossRef558
Teruhisa Takuwa, Fumihiro Tanaka, Kazue Yoneda, Ikuko Torii, Masaki Hashimoto, Yoshitomo Okumura, Seiji Matsumoto, Nobuyuki Kondo, Seiki Hasegawa. (2010) Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report. Lung Cancer 68:3, 498-500
CrossRef559
Lucia Nogova, Matthias Scheffler, Christian Mattonet, Thomas Zander, Jürgen Wolf. (2010) Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. Onkopipeline 3:2, 113-117
CrossRef560
Martin Reck. (2010) A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Review of Anticancer Therapy 10:6, 955-965
CrossRef561
Gyula Ostoros, Balázs Döme, János Strausz, József Tímár. (2010) Változások a nem-kissejtes tüdőrák diagnosztikus és terápiás stratégiájában. Magyar Onkológia 54:2, 137-143
CrossRef562
Tomoya Kawaguchi, Akihide Matsumura, Shimao Fukai, Atsuhisa Tamura, Ryusei Saito, Jason A. Zell, Yosihito Maruyama, Argyrios Ziogas, Masaaki Kawahara, Sai-Hong Ignatius Ou. (2010) Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef563
I.A. Adamietz, N. Niederle. (2010) Lungenkarzinom. Der Onkologe 16:6, 615-628
CrossRef564
(2010) Evolving R&D for emerging markets. Nature Reviews Drug Discovery 9:6, 417-420
CrossRef565
Evandro Fei Fang, Jack Ho Wong, Clara Shui Fern Bah, Peng Lin, Sai Wah Tsao, Tzi Bun Ng. (2010) Bauhinia variegata var. variegata trypsin inhibitor: From isolation to potential medicinal applications. Biochemical and Biophysical Research Communications 396:4, 806-811
CrossRef566
Stephen Y. Lai, Faye M. Johnson. (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resistance Updates 13:3, 67-78
CrossRef567
Lukas C. Heukamp, Reinhard Büttner. (2010) Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. Onkopipeline 3:2, 87-93
CrossRef568
Cesare Gridelli, Andrea Ardizzoni, Jean-Yves Douillard, Nasser Hanna, Christian Manegold, Francesco Perrone, Robert Pirker, Rafael Rosell, Frances A. Shepherd, Luigi De Petris, Massimo Di Maio, Filippo de Marinis. (2010) Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 68:3, 319-331
CrossRef569
C. Peedell, J. Dunning, A. Bapusamy. (2010) Is There a Standard of Care for the Radical Management of Non-small Cell Lung Cancer Involving the Apical Chest Wall (Pancoast Tumours)?. Clinical Oncology 22:5, 334-346
CrossRef570
Eric B. Haura, D. Ross Camidge, Karen Reckamp, Alberto Chiappori, Faye Johnson, Roy Herbst, Kwok Wong, David Carbone. (2010) Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. Journal of Thoracic Oncology 5, S207-S213
CrossRef571
Thomas E Stinchcombe, Suresh S Ramalingam. (2010) Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?. The Lancet Oncology 11:6, 500-501
CrossRef572
Carrie Printz. (2010) Physicians optimistic about advances in lung cancer and melanoma treatment. Cancer 116:10, 2287-2288
CrossRef573
Richard L. Schilsky. (2010) Personalized medicine in oncology: the future is now. Nature Reviews Drug Discovery 9:5, 363-366
CrossRef574
Tomoya Kawaguchi, Minoru Takada, Akihito Kubo, Akihide Matsumura, Shimao Fukai, Atsuhisa Tamura, Ryusei Saito, Masaaki Kawahara, Yosihito Maruyama. (2010) Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis. Journal of Thoracic Oncology1
CrossRef575
Navneet Singh, Amanjit Bal, Ashutosh N Aggarwal, Ashim Das, Digambar Behera. (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncology 6:5, 741-767
CrossRef576
Mark A. Socinski. (2010) The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:3, 149-159
CrossRef577
G. D'Addario, M. Fruh, M. Reck, P. Baumann, W. Klepetko, E. Felip, . (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v116-v119
CrossRef578
Timothy J. R. Harris, Frank McCormick. (2010) The molecular pathology of cancer. Nature Reviews Clinical Oncology 7:5, 251-265
CrossRef579
Dora Dias-Santagata, Sara Akhavanfard, Serena S. David, Kathy Vernovsky, Georgiana Kuhlmann, Susan L. Boisvert, Hannah Stubbs, Ultan McDermott, Jeffrey Settleman, Eunice L. Kwak, Jeffrey W. Clark, Steven J. Isakoff, Lecia V. Sequist, Jeffrey A. Engelman, Thomas J. Lynch, Daniel A. Haber, David N. Louis, Leif W. Ellisen, Darrell R. Borger, A. John Iafrate. (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine 2:5, 146-158
CrossRef580
Wee-Lee Yeo, Gregory J. Riely, Beow Y. Yeap, Michelle W. Lau, Jeremy L. Warner, Kelly Bodio, Mark S. Huberman, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa. (2010) Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations. Journal of Thoracic Oncology1
CrossRef581
Nobuyuki Yamamoto, Yutaka Nishiwaki, Shunichi Negoro, Haiyi Jiang, Yohji Itoh, Nagahiro Saijo, Masahiro Fukuoka. (2010) Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology1
CrossRef582
Tony S. Mok. (2010) A Target or a Demi-Target. Clinical Lung Cancer 11:3, 147-148
CrossRef583
Wen-Zhao Zhong, Yi-Long Wu, Xue-Ning Yang, Ai-Lin Guo, Jian Su, Xu-Chao Zhang, Dong-Lan Luo, Zhen Wang, Hua-Jun Chen, Qing Zhou, Chong-Rui Xu, Gui-Bin Qiao, Ri-Qiang Liao, Jin-Ji Yang, Tony S. Mok. (2010) Genetic Evolution of Epidermal Growth Factor Receptor in Adenocarcinoma With a Bronchioloalveolar Carcinoma Component. Clinical Lung Cancer 11:3, 160-168
CrossRef584
Ruth March. (2010) Delivering on the promise of personalized healthcare. Personalized Medicine 7:3, 327-337
CrossRef585
Egbert F. Smit, Anne-Marie C. Dingemans, Frederik B. Thunnissen, Monique M. Hochstenbach, Robert-Jan van Suylen, Pieter E. Postmus. (2010) Sorafenib in Patients with Advanced Non-small Cell Lung Cancer that Harbor K-Ras Mutations. Journal of Thoracic Oncology 5:5, 719-720
CrossRef586
D Ercan, K Zejnullahu, K Yonesaka, Y Xiao, M Capelletti, A Rogers, E Lifshits, A Brown, C Lee, J G Christensen, D J Kwiatkowski, J A Engelman, P A Jänne. (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29:16, 2346-2356
CrossRef587
A. Potti, R. L. Schilsky, J. R. Nevins. (2010) Refocusing the War on Cancer: The Critical Role of Personalized Treatment. Science Translational Medicine 2:28, 28cm13-28cm13
CrossRef588
O. Gautschi, Miklos Pless. (2010) Swiss trials in thoracic oncology. memo - Magazine of European Medical Oncology 3:1, 37-40
CrossRef589
Kimihide Yoshida, Yasushi Yatabe, Jangchul Park, Shizu Ogawa, Ji Young Park, Junichi Shimizu, Yoshitsugu Horio, Keitaro Matsuo, Tetsuya Mitsudomi, Toyoaki Hida. (2010) Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Journal of Cancer Research and Clinical Oncology 136:4, 527-535
CrossRef590
W. Hilbe. (2010) Changing paradigms in clinical trials. memo - Magazine of European Medical Oncology 3:1, 1-2
CrossRef591
M. Mohr, T. Kessler, U. Krug, P. Hoffknecht, L.H. Schmidt, K. Wiebe, W.E. Berdel, R. Wiewrodt. (2010) Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 24:2, 97-104
CrossRef592
Michel Velez, Astrid Belalcazar, Gelenis Domingo, Marcelo Blaya, Luis E Raez, Edgardo S Santos. (2010) Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Review of Anticancer Therapy 10:4, 549-557
CrossRef593
Peh Sun Loo, Stuart C. Thomas, Marianne C. Nicolson, Margaret N. Fyfe, Keith M. Kerr. (2010) Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens. Journal of Thoracic Oncology 5:4, 442-447
CrossRef594
Andrew G. Nicholson, David Gonzalez, Pallav Shah, Matthew J. Pynegar, Manjiri Deshmukh, Alexandra Rice, Sanjay Popat. (2010) Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis. Journal of Thoracic Oncology 5:4, 436-441
CrossRef595
William D. Travis, Natasha Rekhtman, Gregory J. Riley, Kim R. Geisinger, Hisao Asamura, Elisabeth Brambilla, Kavita Garg, Fred R. Hirsch, Masayuki Noguchi, Charles A. Powell, Valerie W. Rusch, Giorgio Scagliotti, Yasushi Yatabe. (2010) Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology. Journal of Thoracic Oncology 5:4, 411-414
CrossRef596
P. Grätzel. (2010) Onko Update 2010. Der Onkologe 16:4, 417-419
CrossRef597
Alain Makinson, Jean-Louis Pujol, Vincent Le Moing, Helene Peyriere, Jacques Reynes. (2010) Interactions Between Cytotoxic Chemotherapy and Antiretroviral Treatment in Human Immunodeficiency Virus-Infected Patients with Lung Cancer. Journal of Thoracic Oncology 5:4, 562-571
CrossRef598
P. A. Bradbury, D. Tu, L. Seymour, P. K. Isogai, L. Zhu, R. Ng, N. Mittmann, M.-S. Tsao, W. K. Evans, F. A. Shepherd, N. B. Leighl, . (2010) Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. JNCI Journal of the National Cancer Institute 102:5, 298-306
CrossRef599
Nayef A. Alymani, Murray D. Smith, David J. Williams, Russell D. Petty. (2010) Predictive biomarkers for personalised anti-cancer drug use: Discovery to clinical implementation. European Journal of Cancer 46:5, 869-879
CrossRef600
Cesare Gridelli. (2010) Can a decisional algorithm be used in first-line treatment of advanced nonsmall cell lung cancer?. Current Opinion in Oncology 22:2, 77-78
CrossRef601
Luca Toschi, Federico Cappuzzo. (2010) Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology 5:1, 5-17
CrossRef602
Wolfram C.M. Dempke, Tamas Suto, Martin Reck. (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67:3, 257-274
CrossRef603
Adi F. Gazdar. (2010) Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer and Metastasis Reviews 29:1, 37-48
CrossRef604
Mei-Kim Ang, Say-Beng Tan, Wan-Teck Lim. (2010) Phase II clinical trials in oncology: are we hitting the target?. Expert Review of Anticancer Therapy 10:3, 427-438
CrossRef605
Kenichi Suda, Kenji Tomizawa, Tetsuya Mitsudomi. (2010) Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews 29:1, 49-60
CrossRef606
J. Wolf, S. Nitschmann. (2010) Bronchialkarzinom: Genetisches Screening vor Therapiebeginn. Der Internist 51:S1, 303-305
CrossRef607
Linda E. Coate, Frances A. Shepherd. (2010) Maintenance Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef608
Liangping Xia, Yuming Rong, Guifang Guo, Huijuan Qiu, Feifei Zhou, Fang Wang. (2010) Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publications. The Chinese-German Journal of Clinical Oncology 9:3, 137-141
CrossRef609
Brigette BY Ma, Herbert Loong. (2010) Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine 7:2, 121-124
CrossRef610
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef611
Rafael Rosell, Santiago Viteri, Miguel Angel Molina, Susana Benlloch, Miquel Taron. (2010) Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Current Opinion in Oncology 22:2, 112-120
CrossRef612
Tomoya Kawaguchi, Minoru Takada, Akihito Kubo, Akihide Matsumura, Shimao Fukai, Atsuhisa Tamura, Ryusei Saito, Yosihito Maruyama, Masaaki Kawahara, Sai-Hong Ignatius Ou. (2010) Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef613
Corey Langer, Jean-Charles Soria. (2010) The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:2, 82-90
CrossRef614
Rafael Rosell, Teresa Morán, Enric Carcereny, Vanessa Quiroga, Miguel Ángel Molina, Carlota Costa, Susana Benlloch, Miquel Tarón. (2010) Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clinical and Translational Oncology 12:2, 75-80
CrossRef615
L.C. Heukamp, R. Büttner. (2010) Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. Der Pathologe 31:1, 22-28
CrossRef616
Sai-Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell. (2010) A Comparison Study of Clinicopathologic Characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) Patients by Smoking Status. Journal of Thoracic Oncology 5:2, 158-168
CrossRef617
Daniel Rauh. (2010) Inaktive Kinasekonformationen stabilisieren. Nachrichten aus der Chemie 58:2, 118-121
CrossRef618
Joel W. Neal, Lecia V. Sequist. (2010) Targeted therapies: Optimal first-line therapy for NSCLC with EGFR mutations. Nature Reviews Clinical Oncology 7:2, 71-72
CrossRef619
Jean Yves Douillard. (2010) Targeting the target: a step forward for the treatment of non-small-cell lung cancer. The Lancet Oncology 11:2, 104-105
CrossRef620
Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology 11:2, 121-128
CrossRef621
Elias A. Kotteas, Andriani G. Charpidou, Kostas N. Syrigos. (2010) Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anti-Cancer Drugs 21:2, 151-168
CrossRef622
Yelena Y. Janjigian, Kevin McDonnell, Mark G. Kris, Ronglai Shen, Camelia S. Sima, Peter B. Bach, Naiyer A. Rizvi, Gregory J. Riely. (2010) Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. Cancer 116:3, 670-675
CrossRef623
T. Mitsudomi. (2010) Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology 40:2, 101-106
CrossRef624
Laura R. Triano, Hari Deshpande, Scott N. Gettinger. (2010) Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 70:2, 167-179
CrossRef625
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne. (2010) Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer Cell 17:1, 77-88
CrossRef626
Brigette BY Ma, Edwin P Hui, Tony SK Mok. (2010) Population-based differences in treatment outcome following anticancer drug therapies. The Lancet Oncology 11:1, 75-84
CrossRef627
Stephen G. SPIRO, Nichole T. TANNER, Gerard A. SILVESTRI, Sam M. JANES, Eric LIM, Johan F. VANSTEENKISTE, Robert PIRKER. (2010) Lung cancer: Progress in diagnosis, staging and therapy. Respirology 15:1, 44-50
CrossRef628
Jin Hoon Cho, Mi Hyun Kim, Kwang Ha Lee, Ki Uk Kim, Doo Soo Jeon, Hye Kyung Park, Yun Seong Kim, Min Ki Lee, Soon Kew Park. (2010) The Effect of Gefitinib on Immune Response of Human Peripheral Blood Monocyte-Derived Dendritic Cells. Tuberculosis and Respiratory Diseases 69:6, 456
CrossRef629
Minoru Inomata, Toshimichi Miya, Yutaka Kokubo. (2010) Radiation Recall Pneumonitis Induced by Gefitinib in a Patient with Lung Adenocarcinoma and EGFR Mutation. Haigan 50:7, 937-941
CrossRef630
W. Scheithauer, R. Pirker, T. Grünberger, G. Kornek. (2010) VEGF and EGFR inhibition: opening a new door to cancer treatment. European Surgery 42:1, 24-28
CrossRef631
Greg V. Manson, Patrick C. Ma. (2010) Response to Pemetrexed Chemotherapy in Lung Adenocarcinoma-Bronchioloalveolar Carcinoma Insensitive to Erlotinib. Clinical Lung Cancer 11:1, 57-60
CrossRef632
F. Meriggi, A. Zaniboni. (2010) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer. Current Gerontology and Geriatrics Research 2010, 1-8
CrossRef633
Samuel Murray, Mattheos Bobos, Nikolaos Angouridakis, Angelos Nikolaou, Helena Linardou, Evangelia Razis, George Fountzilas. (2010) Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. Journal of Oncology 2010, 1-10
CrossRef634
Nagahiro Saijo, Hirotsugu Kenmotsu. (2010) Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine 49:18, 1923-1934
CrossRef635
Johann C Brandes, Ruhul Amin, Fadlo Khuri, Dong Moon Shin. (2010) Prevention of Lung Cancer: Future Perspective with Natural Compounds. Tuberculosis and Respiratory Diseases 69:1, 1
CrossRef636
Brian Center, William Jeffrey Petty, Diandra Ayala, William H. Hinson, James Lovato, James Capellari, Timothy Oaks, Antonius A. Miller, Arthur William Blackstock. (2010) A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and Maintenance Gefitinib for Patients with Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 69-74
CrossRef637
Kye Young Lee, Hee Joung Kim, Sun Jong Kim, Gwang Ha Yoo, Won Dong Kim, Seo Young Oh, Wan Seop Kim. (2010) PNA-Mediated PCR Clamping for the Detection of EGFR Mutations in Non-Small Cell Lung Cancer. Tuberculosis and Respiratory Diseases 69:4, 271
CrossRef638
Hajime Asahina, Satoshi Oizumi, Akira Inoue, Ichiro Kinoshita, Takashi Ishida, Yuka Fujita, Noriaki Sukoh, Masao Harada, Makoto Maemondo, Yasuo Saijo, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Toshihiro Nukiwa, Masaharu Nishimura. (2010) Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib. Oncology 79:5-6, 423-429
CrossRef639
Wenjun Zhou, Dalia Ercan, Liang Chen, Cai-Hong Yun, Danan Li, Marzia Capelletti, Alexis B. Cortot, Lucian Chirieac, Roxana E. Iacob, Robert Padera, John R. Engen, Kwok-Kin Wong, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:7276, 1070-1074
CrossRef640
(2009) Treatment of Lung Cancer. New England Journal of Medicine 361:25, 2485-2487
Full Text641
R. Sikorski, B. Yao. (2009) Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Science Translational Medicine 1:10, 10ps11-10ps11
CrossRef642
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef643
Andreas-Claudius Hoffmann, Arndt Hartmann, Kurt-Werner Schmid, Martin Schuler. (2009) Biomarker für die individualisierte Behandlung solider Tumoren. Onkopipeline 2:4, 134-140
CrossRef644
Seema Harichand-Herdt, Suresh S. Ramalingam. (2009) Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women. Seminars in Oncology 36:6, 572-580
CrossRef645
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Cancer Reviews 3:1, 9-18
CrossRef646
Danielle Shafer, Kathy Albain. (2009) Lung Cancer Outcomes in Women. Seminars in Oncology 36:6, 532-541
CrossRef647
David R. Gandara, Philip C. Mack, Tianhong Li, Primo N. Lara ., Roy S. Herbst. (2009) Evolving Treatment Algorithms for Advanced Non–Small-Cell Lung Cancer: 2009 Looking Toward 2012. Clinical Lung Cancer 10:6, 392-394
CrossRef648
Ross A Soo, Benjamin O Anderson, Byoung Chul Cho, Chih-Hsin Yang, Meilin Liao, Wan-Teck Lim, Peter Goldstraw, Tony S Mok. (2009) First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1102-1110
CrossRef649
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Lung Cancer 10:6, 395-404
CrossRef650
Mark Sanford, Lesley J. Scott. (2009) Gefitinib. Drugs 69:16, 2303-2328
CrossRef651
Lisa Hutchinson. (2009) Gefitinib efficacy in adenocarcinoma. Nature Reviews Clinical Oncology 6:11, 617-617
CrossRef652
Bethan Hughes. (2009) Lessons from the lung for targeted anticancer drugs. Nature Reviews Drug Discovery 8:10, 758-759
CrossRef653
Gazdar, Adi F., . (2009) Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer. New England Journal of Medicine 361:10, 1018-1020
Full Text654
CIG Media Group, LP. (2009) Highlights From: The 13th World Conference on Lung Cancer. Clinical Lung Cancer 10:5, 317-321
CrossRef655
Helen X. Chen, Jessica N. Cleck, Rochelle Coelho, Janet E. Dancey. (2009) Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer 33:4, 245-294
CrossRef656
Miyako Satouchi. (2009) Selective Use of Gefitinib and Erlotinib on Non-small Cell Lung Cancer Patients. Haigan 49:6, 950-956
CrossRef
- Letters
